Publikationen der Klinik für Strahlentherapie

Stand: 30.10.2024

  1. Güttler A, Darnstaedt E, Knobloch-Sperlich D, Petrenko M, Kessler J, Grosse I, Vordermark D, Bache M. Zinc Influences the Efficacy of Betulinic Acid Treatment and Radiotherapy in Breast Cancer Cells. Antioxidants 2024, 13, 1299. doi: 10.3390/antiox13111299

  2. van der Weijst L, Machingura A, Alanya A, Lidington E, Velikova G, Flechtner HH, Schmidt H, Lehmann J, Ramage JK, Ringash J, Wac K, Oliver K, Taylor KJ, Wintner L, Senna LPC, Koller M, Husson O, Bultijnck R, Wilson R, Singer S, Bjelic-Radisic V, van der Graaf WTA, Pe M; EORTC Quality of Life Group. Improving completion rates of patient-reported outcome measures in cancer clinical trials: Scoping review investigating the implications for trial designs. Eur J Cancer. 2024 Sep 18;212:114313. doi: 10.1016/j.ejca.2024.114313. Epub ahead of print. PMID: 39305741.

  3. Ohlinger J, Vordermark D, Ostheimer C, Bache M, Tzschoppe T, Demircan K, Schomburg L, Medenwald D, Seliger B. Change in the serum selenium level of patients with non-metastatic and metastatic non-small cell lung cancer (NSCLC) during radiotherapy as a predictive factor for survival. Strahlenther Onkol. 2024 Sep 6. doi: 10.1007/s00066-024-02276-w. Epub ahead of print. PMID: 39240366.

  4. Moustakis C, Blanck O, Grohmann M, Albers D, Bartels D, Bathen B, Borzì GR, Broggi S, Bruschi A, Casale M, Delana A, Doolan P, Tazehmahalleh FE, Fabiani S, Falco MD, Fehr R, Friedlein M, Gutser S, Hamada A, Hancock T, Köhn J, Kornhuber C, Krieger T, Lambrecht U, Lappi S, Moretti E, Mirus A, Muedder T, Plaude S, Polvika B, Ravaglia V, Righetto R, Rinaldin G, Schachner H, Scaggion A, Schilling P, Szeverinski P, Villaggi E, Walke M, Wilke L, Winkler P, Nicolay NH, Eich HT, Gkika E, Brunner TB, Schmitt D. Planning Benchmark Study for Stereotactic Body Radiation Therapy of Pancreas Carcinomas with Simultaneously Integrated Boost and Protection: Results of the DEGRO/DGMP Working Group on Stereotactic Radiation Therapy and Radiosurgery. Int J Radiat Oncol Biol Phys. 2024 Aug 31:S0360-3016(24)03315-7. doi: 10.1016/j.ijrobp.2024.08.038. Epub ahead of print. PMID: 39222825.

  5. Müller JA, Vordermark D. Stellenwert einer „targeted therapy“ beim EGFR-mutierten Lungenkarzinom nach erfolgter Radiochemotherapie [Targeted therapy in EGFR-mutated lung cancer following chemoradiotherapy]. Strahlenther Onkol. 2024 Aug 2. German. doi: 10.1007/s00066-024-02284-w. Epub ahead of print. PMID: 39095648.

  6. Ronellenfitsch U, Friedrichs J, Barbier E, Bass GA, Burmeister B, Cunningham D, Eyck BM, Grilli M, Hofheinz RD, Kieser M, Kleeff J, Klevebro F, Langley R, Lordick F, Lutz M, Mauer M, Michalski CW, Michl P, Nankivell M, Nilsson M, Seide S, Shah MA, Shi Q, Stahl M, Urba S, van Lanschot J, Vordermark D, Walsh TN, Ychou M, Proctor T, Vey JA. Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction: A Network Meta-Analysis. JAMA Netw Open. 2024 Aug 1;7(8):e2425581. doi: 10.1001/jamanetworkopen.2024.25581. PMID: 39093560.

  7. Damek A, Kurch L, Franke FC, Attarbaschi A, Beishuizen A, Cepelova M, Ceppi F, Daw S, Dieckmann K, Fernández-Teijeiro A, Feuchtinger T, Flerlage JE, Fosså A, Georgi TW, Hasenclever D, Hraskova A, Karlen J, Klekawka T, Kluge R, Körholz D, Landman-Parker J, Leblanc T, Mauz-Körholz C, Metzler M, Pears J, Steglich J, Uyttebroeck A, Vordermark D, Wallace WH, Wohlgemuth WA, Stoevesandt D. Hodgkin lymphoma: hypodense lesions in mediastinal masses. Sci Rep. 2024 Jun 25;14(1):14591. doi: 10.1038/s41598-024-64253-8. PMID: 38918503; PMCID: PMC11199705.

  8. Reitz M, Berling-Ernst A, Schminke T, Brandes M, Meurer J, Fuhr D, Tramm I, Gadczikowkse Y, Welker C, Baurecht H, Morlok D, Rüter J, Herrmann-Johns A, Jensen W, Bokemeyer C, Schmidt T, Köser A, Golla A, Schmidt H, Jahn P, Zimmer R, Götte M,
    Theurich S, Wehner A, Madl B, Halle M, Hegenberg K, Laxy M, Leitzmann M, Zeeb H, Baumann FT. IMPLEMENT – Ein Modellprojekt zur sektorenübergreifenden Implementierung einer flächendeckenden und qualitätsgesicherten Sport- und
    Bewegungstherapie bei Krebs. Bewegungstherapie und Gesundheitssport 2024; 40: 69–73. Georg Thieme Verlag Stuttgart. doi: 10.1055/a-2255-1433

  9. Tempfer C, Fehm T, Vordermark D, Marnitz-Schulze S, Beckmann MW, Denschlag D, Brucker S, Wallwiener M, Eichbaum M, Ataseven B, Hillemanns P. Statement of the Uterus Commission of the Gynecological Oncology Working Group (AGO) on Neoadjuvant Chemotherapy Prior to Definitive Radiochemotherapy in Patients with Locally Advanced Cervical Cancer. Geburtshilfe Frauenheilkunde 2024, Georg Thieme Verlag Stuttgart. doi: 10.1055/a-2279-3163.

  10. Bache M, Heise NV, Thiel A, Funtan A, Seifert F, Petrenko M, Güttler A, Brandt S, Mueller T, Vordermark D, Thondorf I, Csuk R, Paschke R. Combination of Betulinic Acid Fragments and Carbonic Anhydrase Inhibitors-A New Drug Targeting Approach. Pharmaceutics. 2024 Mar 14;16(3):401. doi: 10.3390/pharmaceutics16030401. PMID: 38543295; PMCID: PMC10974084.

  11. Stoevesandt D, Ludwig C, Mauz-Körholz C, Körholz D, Hasenclever D, McCarten K, Flerlage JE, Kurch L, Wohlgemuth WA, Landman-Parker J, Wallace WH, Fosså A, Vordermark D, Karlén J, Cepelová M, Klekawka T, Attarbaschi A, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Steglich J. Pulmonary lesions in early response assessment in pediatric Hodgkin lymphoma: prevalence and possible implications for initial staging. Pediatr Radiol. 2024 Jan 31. doi: 10.1007/s00247-024-05859-y. Epub ahead of print. PMID: 38296856.

  12. Hassan L, Bedir A, Kraus FB, Ostheimer C, Vordermark D, Mikolajczyk R, Seliger B, Medenwald D. Correlation of Increased Soluble Tumor Necrosis Factor Receptor 1 with Mortality and Dependence on Treatment in Non-Small-Cell Lung Cancer Patients: A Longitudinal Cohort Study. Cancers 2024, 16, 525. doi: 10.3390/cancers16030525.

  1. Mehjardi NZ, Kessler J, Sanin AY, Picard D, Westhoff P, Nickel AC, Uhlmann C, Shi W, Steiger HJ, Remke M, Fischer I, Vordermark D, Croner RS, Kahlert UD. The development of a hiPSC-based platform to identify tissue-dependencies of IDH1 R132H. Cell Death Discov. 2023 Dec 12;9(1):452. doi: 10.1038/s41420-023-01747-w. PMID: 38086797.

  2. Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. [S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 2: Epidemiologie und Ätiologie, Diagnostik, Therapie des invasiven Plattenepithelkarzinoms der Haut, Nachsorge und Prävention: S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention]. J Dtsch Dermatol Ges. 2023 Nov;21(11):1422-1434. German. doi: 10.1111/ddg.15256_g. PMID: 37946644.

  3. Vordermark D, Schmidt H. Deeskalation der Strahlentherapie bei älteren Patient:innen. Onkologie (2023). doi: 10.1007/s00761-023-01430-w

  4. Schütte W, Gütz S, Nehls W, Blum TG, Brückl W, Buttmann-Schweiger N, Büttner R, Christopoulos P, Delis S, Deppermann KM, Dickgreber N, Eberhardt W, Eggeling S, Fleckenstein J, Flentje M, Frost N, Griesinger F, Grohé C, Gröschel A, Guckenberger M, Hecker E, Hoffmann H, Huber RM, Junker K, Kauczor HU, Kollmeier J, Kraywinkel K, Krüger M, Kugler C, Möller M, Nestle U, Passlick B, Pfannschmidt J, Reck M, Reinmuth N, Rübe C, Scheubel R, Schumann C, Sebastian M, Serke M, Stoelben E, Stuschke M, Thomas M, Tufman A, Vordermark D, Waller C, Wolf J, Wolf M, Wormanns D. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms [Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer - Interdisciplinary Guideline of the German Respiratory Society and the German Cancer Society - Abridged Version]. Pneumologie. 2023 Oct;77(10):671-813. German. doi: 10.1055/a-2029-0134. Epub 2023 Oct 26. PMID: 37884003.

  5. Fietkau R, Höller U, van Kampen M, Krause M, Petersen C, Vordermark D. Deutsche Gesellschaft für Radioonkologie (DEGRO) mahnt stationäre strahlentherapeutische Versorgung an : Stellungnahme zu einem Urteil des Bundessozialgerichts vom 29.08.2023 zur Erbringung stationärer strahlentherapeutischer Leistungen. Strahlenther Onkol. 2023 Oct 23. German. doi: 10.1007/s00066-023-02169-4. Epub ahead of print. PMID: 37872397.

  6. Müller JA, Kluttig A, Medenwald D. Leitlinienassoziierte Versorgungsforschung in der Onkologie unter Nutzung von Registerdaten. Forum (2023). doi: 10.1007/s12312-023-01263-z

  7. Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care. J Dtsch Dermatol Ges. 2023 Oct;21(10):1249-1262. doi: 10.1111/ddg.15231. PMID: 37845077.

  8. Heppt MV, Leiter U, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, El Gammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. S3-Leitlinie "Aktinische Keratose und Plattenepithelkarzinom der Haut" - Update 2023, Teil 1: Therapie der aktinischen Keratose, Morbus Bowen, Cheilitis actinica, berufsbedingte Erkrankung und Versorgungsstrukturen: S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma"- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care. J Dtsch Dermatol Ges. 2023 Oct;21(10):1249-1262. doi: 10.1111/ddg.15231_g. PMID: 37845050.

  9. Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, ElGammal AKS, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. S3 guideline "actinic keratosis and cutaneous squamous cell carcinoma" - update 2023, part 2: epidemiology and etiology, diagnostics, surgical and systemic treatment of cutaneous squamous cell carcinoma (cSCC), surveillance and prevention. J Dtsch Dermatol Ges. 2023 Oct 15. doi: 10.1111/ddg.15256. Epub ahead of print. PMID: 37840404.

  10. Leiter U, Heppt MV, Steeb T, Alter M, Amaral T, Bauer A, Bechara FG, Becker JC, Breitbart EW, Breuninger H, Diepgen T, Dirschka T, Eigentler T, Stephan El Gammal AK, Felcht M, Flaig MJ, Follmann M, Fritz K, Grabbe S, Greinert R, Gutzmer R, Hauschild A, Hillen U, Ihrler S, John SM, Kofler L, Koelbl O, Krause-Bergmann A, Kraywinkel K, Krohn S, Langer T, Loquai C, Löser CR, Mohr P, Nashan D, Nothacker M, Pfannenberg C, Salavastru C, Schmitz L, Stockfleth E, Szeimies RM, Ulrich C, Voelter-Mahlknecht S, Vordermark D, Weichenthal M, Welzel J, Wermker K, Wiegand S, Garbe C, Berking C. German S3 guideline “actinic keratosis and cutaneous squamous cell carcinoma” – Long version of the update 2023, EJC Skin Cancer, Volume 1, 2023, 100004, ISSN 2772-6118, doi: 10.1016/j.ejcskn.2023.100004.

  11. Müller JA, Delank KS, Laudner K, Wittenberg I, Zeh A, Vordermark D, Medenwald D. Clinical characteristics of sarcoma patients: a population-based data analysis from a German clinical cancer registry. J Cancer Res Clin Oncol. 2023 Sep 26. doi: 10.1007/s00432-023-05350-5. Epub ahead of print. PMID: 37750956.

  12. Mehlhorn I, Heichel J, Wohlgemuth W, Skalej M, Izaguirre V, Dießel L, Kisser U, Viestenz A, Wienrich R. Interdisziplinäres Management einer kombinierten vaskulären Malformation der Orbita [Interdisciplinary management of a combined vascular malformation of the orbit]. Ophthalmologie. 2023 Aug 25. German. doi: 10.1007/s00347-023-01900-x. Epub ahead of print. PMID: 37624390.

  13. Bedir A, Mehrotra S, Gnüchtel J, Vordermark D, Medenwald D. Treatment patterns in stage III non‑small‑cell lung cancer patients: a population‑based study using German cancer registry data. J Cancer Res Clin Oncol. 2023 Aug 30. doi: 10.1007/s00432-023-05289-7. Epub ahead of print. PMID: 37648808.

  14. Abu-Rumeileh S, Barba L, Bache M, Halbgebauer S, Oeckl P, Steinacker P, Güttler A, Keßler J, Illert J, Strauss C, Vordermark D, Otto M. Plasma β-synuclein, GFAP, and neurofilaments in patients with malignant gliomas undergoing surgical and adjuvant therapy. Ann Clin Transl Neurol. 2023 Aug 23. doi: 10.1002/acn3.51878. Epub ahead of print. PMID: 37608748.

  15. Beutner K, Medenwald D, Meyer G. Sektorenübergreifende Versorgungsverläufe von Patient*innen mit kolorektalem Karzinom in Sachsen-Anhalt [Cross-sectoral care trajectories of patients with colorectal cancer in Saxony-Anhalt]. Gesundheitswesen. 2023 Aug 10. German. doi: 10.1055/a-2106-9644. Epub ahead of print. PMID: 37562409.

  16. Bache M, Kadler F, Struck O, Medenwald D, Ostheimer C, Güttler A, Keßler J, Kappler M, Riemann A, Thews O, Seliger B, Vordermark D. Correlation between Circulating miR-16, miR-29a, miR-144 and miR-150, and the Radiotherapy Response and Survival of Non-Small-Cell Lung Cancer Patients. Int J Mol Sci. 2023 Aug 16;24(16):12835. doi: 10.3390/ijms241612835. PMID: 37629015

  17. Pilz MJ, Rothmund M, Lidington E, Piccinin C, Arraras JI, Groenvold M, Holzner B, van Leeuwen M, Petersen MA, Schmidt H, Young T, Giesinger JM; EORTC Quality of Life Group. Content comparison of the EORTC CAT Core, SF-36, FACT-G, and PROMIS role and social functioning measures based on the International Classification of Functioning, Disability and Health. Psychooncology. 2023 Jul 25. DOI: 10.1002/pon.6188. Epub ahead of print. PMID: 37491796.

  18. Scheer M, Spindler K, Strauss C, Schob S, Dietzel CT, Leisz S, Prell J, Rampp S. Surgical Site Infections in Glioblastoma Patients-A Retrospective Analysis. J Pers Med. 2023 Jul 10;13(7):1117. doi: 10.3390/jpm13071117. PMID: 37511730

  19. Broscheit S, Vordermark D, Gerlach R, Gernhardt CR. Impact of Preceded Tumor Therapeutic Irradiation on the Microtensile Bond Strength of Universal Adhesives Applied in Self-Etch Mode to Human Dentin In Vitro. Appl. Sci. 2023, 13, 7873. DOI: 10.3390/app13137873

  20. Hassel JC, Zimmer L, Sickmann T, Eigentler TK, Meier F, Mohr P, Pukrop T, Roesch A, Vordermark D, Wendl C et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448. DOI: 10.3390/cancers15133448

  21. Vordermark, D, Gruber, I. & Kölbl, O. Strahlentherapie des Melanoms. Onkologie (2023). DOI: 10.1007/s00761-023-01375-0

  22. Gkika E, Kostyszyn D, Fechter T, Moustakis C, Ernst F, Boda-Heggemann J, Sarria G, Dieckmann K, Dobiasch S, Duma MN, Eberle F, Kroeger K, Häussler B, Izaguirre V, Jazmati D, Lautenschläger S, Lohaus F, Mantel F, Menzel J, Pachmann S, Pavic M, Radlanski K, Riesterer O, Gerum S, Röder F, Willner J, Barczyk S, Imhoff D, Blanck O, Wittig A, Guckenberger M, Grosu AL, Brunner TB. Interobserver agreement on definition of the target volume in stereotactic radiotherapy for pancreatic adenocarcinoma using different imaging modalities. Strahlenther Onkol. 2023 Nov;199(11):973-981. doi: 10.1007/s00066-023-02085-7. Epub 2023 Jun 2. PMID: 37268767; PMCID: PMC10598103.

  23. Schmidt H, Steckelberg A, Grohmann E, Weise S, Vordermark D. Gemeinsam mit Patient*innen für Patient*innen - Partizipative Gesundheitsforschung im Kontext der Strahlentherapie [With patients, for patients - Participative health care research in the context of radiotherapy]. Forum 2023. DOI: 10.1007/s12312-023-01220-w. Epub 2023 Jun 22.

  24. Fietkau R, Höller U, Krause M, Petersen C, van Kampen M, Vordermark D, Willner J. Strukturelle, prozedurale und personelle Voraussetzung für die Erbringung radioonkologischer und strahlentherapeutischer Leistungen 2023 in Deutschland – ein Positionspapier der Deutschen Gesellschaft für Radioonkologie (DEGRO) [Structural, procedural, and personnel requirements for provision of radiation oncology and radiation therapy services in Germany in 2023-a position paper of the German Society of Radiation Oncologists (DEGRO)]. Strahlenther Onkol. 2023 Jun 19. German. DOI: 10.1007/s00066-023-02105-6. Epub ahead of print. PMID: 37336797.

  25. Rothmund M, Pilz MJ, Egeter N, Lidington E, Piccinin C, Arraras JI, Grønvold M, Holzner B, van Leeuwen M, Petersen MA, Schmidt H, Young T, Giesinger JM; EORTC Quality of Life Group. Patient-reported outcome measures for emotional functioning in cancer patients: Content comparison of the EORTC CAT Core, FACT-G, HADS, SF-36, PRO-CTCAE, and PROMIS instruments. Psychooncology. 2023 Apr;32(4):628-639. DOI: 10.1002/pon.6109. Epub 2023 Feb 19. PMID: 36707461.

  26. Pilleron S, Sun V, Ayala AP, Haase KR, Arthur EK, Kenis C, Roggendorf S, Krok-Schoen JL, Trevino K, Schmidt H, Hannan M, Nikita N, Monginot S, Navarrete E, Puts M. Loneliness in older adults living with cancer: A scoping review of the quantitative and qualitative evidence on behalf of the International Society of Geriatric Oncology Nursing and Allied Health Interest Group. J Geriatr Oncol. 2023 Jun;14(5):101519. DOI: 10.1016/j.jgo.2023.101519. Epub 2023 May 11. PMID: 37179207.

  27. Franke FC, Damek A, Steglich J, Kurch L, Hasenclever D, Georgi TW, Wohlgemuth WA, Mauz-Körholz C, Körholz D, Kluge R, Landman-Parker J, Wallace WH, Fosså A, Vordermark D, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Attarbaschi A, Ceppi F, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Moellers M, Buerke B, Stoevesandt D. Differentiation between rebound thymic hyperplasia and thymic relapse after chemotherapy in pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2023 May 27:e30421. DOI: 10.1002/pbc.30421. Epub ahead of print. PMID: 37243889.

  28. Kornhuber C, Ensminger S, Hübsch P, Janich M, Leucht CA, Vordermark D, Dietzel CT. Feasibility of a simultaneously integrated boost concept for hypofractionated stereotactic radiotherapy of unresected brain metastases. Radiat Oncol. 2023 May 22;18(1):88. DOI: 10.1186/s13014-023-02266-9. PMID: 37217934.

  29. Oertel M, Hering D, Baues C, Kittel C, Fuchs M, Kriz J, Kröger K, Vordermark D, Herfarth K, Engenhart-Cabillic R, Lukas P, Haverkamp U, Borchmann P, Eich HT. Radiation doses to mediastinal organs at risk in early-stage unfavorable Hodgkin lymphoma- a risk stratified analysis of the GHSG HD17 trial. Front Oncol. 2023 May 5;13:1183906. DOI: 10.3389/fonc.2023.1183906. PMID: 37213291; PMCID: PMC10196378.

  30. Jacob J, Vordermark D, Lorenz K, Medenwald D. Prognostic factors in radiotherapy of anaplastic thyroid carcinoma: a single center study over 31 years. Radiat Oncol. 18, 71 (2023). DOI: 10.1186/s13014-023-02249-w

  31. Kassik MT, Vordermark D, Kornhuber C, Medenwald D. Factors associated with overall survival, progression-free survival and toxicity in patients with small cell lung cancer and thoracic irradiation in a clinical real-world setting. Radiat Oncol.18, 70 (2023). DOI: 10.1186/s13014-023-02252-1

  32. Vordermark D, Höller U. The role of radiotherapy in the updated German S2k guideline for management of Merkel cell carcinoma. Strahlenther Onkol. 2023 Mar 28. DOI: 10.1007/s00066-023-02068-8. Epub ahead of print. PMID: 36976298.

  33. Becker JC, Beer AJ, DeTemple VK, Eigentler T, Flaig M, Gambichler T, Grabbe S, Höller U, Klumpp B, Lang S, Pföhler C, Posch C, Prasad V, Schlattmann P, Schneider-Burrus S, Ter-Nedden J, Terheyden P, Thoms K, Vordermark D, Ugurel S. S2k Guideline - Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) - Update 2022. J Dtsch Dermatol Ges. 2023 Mar;21(3):305-320. DOI: 10.1111/ddg.14930. PMID: 36929552.

  34. Müller JA, Vordermark D, Medenwald D. Mortality after radiotherapy or surgery in the treatment of early-stage non-small-cell lung cancer: a population-based data analysis in the clinical cancer registry of Brandenburg-Berlin. Strahlenther Onkol. 2023 Mar 13. DOI: 10.1007/s00066-023-02055-z. Epub ahead of print. PMID: 36912978.

  35. Müller JA, Trommer S, Meyer F, Lampe K, Croner RS, Vordermark D, Medenwald D. Was muss der Allgemein- und Viszeralchirurg von der onkologisch ausgerichteten Strahlentherapie wissen? [What does the general and abdominal surgeon need to know about oncologically oriented radiotherapy?]. Chirurgie(Heidelb). 2023 Mar 9. German. DOI: 10.1007/s00104-023-01820-1. Epub ahead of print. PMID: 36892602.

  36. Sreenivasa S, Wösle M, Gager Y, Vordermark D, Grajewski L, Krause L, Ciernik IF. Impact of tumour volume and treatment delay on the outcome after linear accelerator-based fractionated stereotactic radiosurgery of uveal melanoma. Br J Ophthalmol. 2023 Mar 9:bjo-2022-322750. DOI: 10.1136/bjo-2022-322750. Epub ahead of print. PMID: 36894300.

  37. Mauz-Körholz C, Landman-Parker J, Fernández-Teijeiro A, Attarbaschi A, Balwierz W, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Ceppi F, Claviez A, Daw S, Dieckmann K, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH, Kluge R. Response-adapted omission of radiotherapy in children and adolescents with early-stage classical Hodgkin lymphoma and an adequate response to vincristine, etoposide, prednisone, and doxorubicin (EuroNet-PHL-C1): a titration study. Lancet Oncol. 2023; 24(3): 252-261. DOI:10.1016/S1470-2045(23)00019-0

  38. Roggendorf S Weise S, Michl P, Vordermark D, Steckelberg A, Schmidt H. Soziale Beziehungen im Verlauf einer Krebserkrankung bei älteren Patient:innen. Eine retrospektive qualitative ­Untersuchung. Familiendynamik. 2023, Heft 1, S. 26-37. DOI:10.21706/fd-48-1-26

  39. Oertel M, Hering D, Nacke N, Kittel C, Kröger K, Kriz J, Fuchs M, Baues C, Vordermark D, Engenhart-Cabillic R, Herfarth K, Lukas P, Schmidberger H, Marnitz S, Borchmann P, Engert A, Haverkamp U, Eich HT. Radiation Therapy in the German Hodgkin Study Group HD 16 and HD 17 Trials: Quality Assurance and Dosimetric Analysis for Hodgkin Lymphoma in the Modern Era. Adv Radiat Oncol. 2022 Dec 30;8(3):101169. DOI: 10.1016/j.adro.2022.101169. PMID: 36896214; PMCID: PMC9991533.

  40. Güttler A, Weinholdt C, Ruff E, Reidt J, Darnstaedt E, Wildemann A, Petrenko M, Keßler J, Kappler M, Grosse I, Vordermark D, Bache M. SESN2 Knockdown Increases Betulinic Acid-Induced Radiosensitivity of Hypoxic Breast Cancer Cells. Cells. 2022 Dec 31;12(1):177. DOI: 10.3390/cells12010177. PMID: 36611970

  1. Güttler A, Weinholdt C, Ruff E, Reidt J, Darnstaedt E, Wildemann A, Petrenko M, Keßler J, Kappler M, Grosse I, Vordermark D, Bache M. SESN2 Knockdown Increases Betulinic Acid-Induced Radiosensitivity of Hypoxic Breast Cancer Cells. Cells. 2022 Dec 31;12(1):177. doi: 10.3390/cells12010177. PMID: 36611970

  2. Denschlag D, Ackermann S, Battista MJ, Cremer W, Egerer G, Fehr M, Follmann M, Haase H, Harter P, Hettmer S, Horn LC, Juhasz-Boess I, Kast K, Köhler G, Kröncke T, Lindel K, Mallmann P, Meyer-Steinacker R, Mustea A, Petru E, Reichardt P, Schmidt D, Strauss HG, Thiel F, Ulrich UA, Vogl T, Vordermark D, Wallwiener M, Gass P, Beckmann MW. Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021). Geburtshilfe Frauenheilkd. 2022 Dec 1;82(12):1337-1367. doi: 10.1055/a-1897-5124. PMID: 36467974; PMCID: PMC9715351.

  3. Nordhausen T, Vordermark D, Al-Ali HK, Schmidt H. Patient-Reported Outcomes in klinischer Praxis. best practice onkologie17, 636–646 (2022). doi:10.1007/s11654-022-00444-x

  4. Gnüchtel J, Vordermark D, Medenwald D. Survey of treatment and care practices in small-cell lung cancer among German radiation oncologists. Strahlenther Onkol. 2022 Nov 23. doi: 10.1007/s00066-022-02019-9. Epub ahead of print. PMID: 36418442.

  5. Roesch J, Oertel M, Wegen S, Trommer M, Schleifenbaum J, Hering D, Mäurer M, Knippen S, Dobiasch S, Waltenberger M, von der Grün J, Medenwald D, Süß C, Hoeck M, Käsmann L, Fleischmann DF, Rühle A, Nicolay NH, Fabian A, Löser A, Heß S, Tamaskovics B, Vinsensia M, Hecht M; Young DEGRO Group. Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer - Results of a large multicenter analysis. Radiother Oncol. 2022 Oct 20:S0167-8140(22)04502-9. doi: 10.1016/j.radonc.2022.10.007. Epub ahead of print. PMID: 36273736.

  6. Schweyen R, Reich W, Vordermark D, Kuhnt T, Wienke A, Hey J. Factors Influencing the Survival Rate of Teeth and Implants in Patients after Tumor Therapy to the Head and Neck Region-Part 1: Tooth Survival. J Clin Med. 2022 Oct 21;11(20):6222. doi: 10.3390/jcm11206222. PMID: 36294543; PMCID: PMC9605197.

  7. Nordhausen T, Lampe K, Vordermark D, Holzner B, Al-Ali HK, Meyer G, Schmidt H. An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology. J Patient Rep Outcomes. 2022 Jul 19;6(1):77. doi: 10.1186/s41687-022-00478-3. PMID: 35852715.

  8. Harke NN, Wagner C, Hermann RM, Hadaschik BA, Radtke JP, Altay-Langguth A, Aufderklamm S, Bach C, Becker-Schiebe M, Blana A, Bruns F, Buse S, Combs SE, Engels CL, Ezzibdeh E, Fiedler M, Fischer LA, Farzat M, Frismann A, Heck MM, Henkenberens C, Roesch MC, Käding C, Klautke G, Krausewitz P, Kuczyk MA, Leitsmann C, Lettmaier S, Mahjoub S, Manseck A, Medenwald D, Meyer A, Micke O, Moritz R, Ott M, Peters I, Pokupic S, Porres D, Preisser F, Reichel K, Schneider A, Schwentner C, Scobioala S, Truss M, Wegener D, Wezel F, Willborn K, Witt JH, Wittig A, Wittlinger M, Wolff HA, Zimmermanns V, Christiansen H. Lessons learned after one year of COVID-19 from a urologist and radiotherapist view: A German survey on prostate cancer diagnosis and treatment. PLoS One. 2022 Jun 14;17(6):e0269827. doi: 10.1371/journal.pone.0269827. PMID: 35700180; PMCID: PMC9197019.

  9. Abera SF, Bedir A, Glowka A, Vordermark D, Medenwald D. Suboptimal use of hormonal therapy among German men with localized high-risk prostate Cancer during 2005 to 2015: analysis of registry data. BMC Cancer. 2022 Jun 7;22(1):624. doi: 10.1186/s12885-022-09677-z. PMID: 35672732; PMCID: PMC9171996.

  10. Shehu E, Roggendorf S, Golla A, Koenig A, Stangl GI, Diestelhorst A, Medenwald D, Vordermark D, Steckelberg A, Schmidt H. Development and Evaluation of a Multimodal Supportive Intervention for Promoting Physical Function in Older Patients with Cancer. Cancers (Basel). 2022 May 24;14(11):2599. doi: 10.3390/cancers14112599. PMID: 35681580; PMCID: PMC9179325.

  11. Buergy D, Würschmidt F, Gkika E, Hörner-Rieber J, Knippen S, Gerum S, Balermpas P, Henkenberens C, Voglhuber T, Kornhuber C, Barczyk S, Röper B, Rashid A, Blanck O, Wittig A, Herold HU, Brunner TB, Sweeney RA, Kahl KH, Ciernik IF, Ottinger A, Izaguirre V, Putz F, König L, Hoffmann M, Combs SE, Guckenberger M, Boda-Heggemann J. Stereotactic body radiotherapy of adrenal metastases-A dose-finding study. Int J Cancer. 2022 Aug 1;151(3):412-421. doi: 10.1002/ijc.34017. Epub 2022 Apr 13. PMID: 35383919.

  12. Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2022 Jan;23(1):125-137. doi: 10.1016/S1470-2045(21)00470-8. Epub 2021 Dec 9. Erratum in: Lancet Oncol. 2022 Feb;23(2):e59. PMID: 34895479; PMCID: PMC8716340.

  13. Moustakis C, Blanck O, Chan MKH, Boda-Heggemann J, Andratschke N, Duma MN, Albers D, Bäumer C, Fehr R, Körber SA, Schmidhalter D, Alraun M, Baus WW, Beckers E, Dierl M, Droege S, Ebrahimi Tazehmahalleh F, Fleckenstein J, Guckenberger M, Heinz C, Henkenberens C, Hennig A, Köhn J, Kornhuber C, Krieger T, Loutfi-Krauss B, Mayr M, Oechsner M, Pfeiler T, Pollul G, Schöffler J, Tümmler H, Ullm C, Walke M, Weigel R, Wertman M, Wiehle R, Wiezorek T, Wilke L, Wolf U, Eich HT, Schmitt D. Planning Benchmark Study for Stereotactic Body Radiation Therapy of Liver Metastases: Results of the DEGRO/DGMP Working Group on Stereotactic Radiation Therapy and Radiosurgery. Int J Radiat Oncol Biol Phys. 2022 Jan 22:S0360-3016(22)00018-9. doi: 10.1016/j.ijrobp.2022.01.008. Epub ahead of print. PMID: 35074434.

  14. Fehm T, Stübs FA, Koch MC, Mallmann P, Dannecker C, Dietl A, Sevnina A, Mergel F, Lotz L; Carolin C.Hack, Ehret A, Gantert D, Martignoni F, Cieslik JP, Menke J, Ortmann O, Stromberger C, Oechsle K, Hornemann B, Mumm F, Grimm C, Sturdza A, Wight E, Loessl K, Golatta M, Hagen V, Dauelsberg T, Diel I, Münstedt K, Merz E, Vordermark D, Lindel K, Wittekind C, Küppers V, Lellé R, Neis K, Griesser H, Pöschel B, Steiner M, Freitag U, Gilster T, Schmittel A, Friedrich M, Haase H, Gebhardt M, Kiesel L, Reinhardt M, Kreißl M, Kloke M, Horn LC, Wiedemann R, Marnitz S, Letsch A, Zraik I, Mangold B, Möckel J, Alt C, Wimberger P, Hillemanns P, Paradies K, Mustea A, Denschlag D, Henscher U, Tholen R, Wesselmann S, Beckmann MW. Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities. Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):181-205. doi: 10.1055/a-1671-2446. PMID: 35197803; PMCID: PMC8855983.

  15. Beckmann MW, Stübs FA, Koch MC, Mallmann P, Dannecker C, Dietl A, Sevnina A, Mergel F, Lotz L, Hack CC, Ehret A, Gantert D, Martignoni F, Cieslik JP, Menke J, Ortmann O, Stromberger C, Oechsle K, Hornemann B, Mumm F, Grimm C, Sturdza A, Wight E, Loessl K, Golatta M, Hagen V, Dauelsberg T, Diel I, Münstedt K, Merz E, Vordermark D, Lindel K, Wittekind C, Küppers V, Lellé R, Neis K, Griesser H, Pöschel B, Steiner M, Freitag U, Gilster T, Schmittel A, Friedrich M, Haase H, Gebhardt M, Kiesel L, Reinhardt M, Kreißl M, Kloke M, Horn LC, Wiedemann R, Marnitz S, Letsch A, Zraik I, Mangold B, Möckel J, Alt C, Wimberger P, Hillemanns P, Paradies K, Mustea A, Denschlag D, Henscher U, Tholen R, Wesselmann S, Fehm T. Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy. Geburtshilfe Frauenheilkd. 2022 Feb 11;82(2):139-180. doi: 10.1055/a-1671-2158.  eCollection 2022 Feb. PMID: 35169387

  16. Mäurer M, Käsmann L, Fleischmann DF, Oertel M, Jazmati D, Medenwald D; Young DEGRO Trial Group. PET/CT-based adaptive radiotherapy of locally advanced non-small cell lung cancer in multicenter yDEGRO ARO 2017-01 cohort study. Radiat Oncol. 2022 Feb 9;17(1):29. doi: 10.1186/s13014-022-01997-5. PMID: 35139856; PMCID: PMC8827193.
  17. Dapper H, Belka C, Bock F, Budach V, Budach W, Christiansen H, Debus J, Distel L, Dunst J, Eckert F, Eich H, Eicheler W, Engenhart-Cabillic R, Fietkau R, Fleischmann DF, Frerker B, Giordano FA, Grosu AL, Herfarth K, Hildebrandt G, Kaul D, Kölbl O, Krause M, Krug D, Martin D, Matuschek C, Medenwald D, Nicolay NH, Niewald M, Oertel M, Petersen C, Pohl F, Raabe A, Rödel C, Rübe C, Schmalz C, Schmeel LC, Steinmann D, Stüben G, Thamm R, Vordermark D, Vorwerk H, Wiegel T, Zips D, Combs SE. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol. 2022 Jan;198(1):1-11. doi: 10.1007/s00066-021-01861-7. Epub 2021 Nov 16. PMID: 34786605; PMCID: PMC8594460.
  18. Bedir A, Abera SF, Vordermark D, Medenwald D. Socioeconomic disparities in endometrial cancer survival in Germany: a survival analysis using population-based cancer registry data. J Cancer Res Clin Oncol. 2022 Jan 22. doi: 10.1007/s00432-021-03908-9. Online ahead of print. PMID: 35064816.
  19. Medenwald D, Brunner T, Christiansen H, Kisser U, Mansoorian S, Vordermark D, Prokosch HU, Seuchter SA, Kapsner LA; our MII research group. Shift of radiotherapy use during the first wave of the COVID-19 pandemic? An analysis of German inpatient data. Strahlenther Onkol. 2022 Jan 7:1–12. doi: 10.1007/s00066-021-01883-1. Epub ahead of print. PMID: 34994804; PMCID: PMC8739685.

  1. Werner C, Stangl S, Salvermoser L, Schwab M, Shevtsov M, Xanthopoulos A, Wang F, Dezfouli AB, Thölke D, Ostheimer C, Medenwald D, Windberg M, Bache M, Schlapschy M, Skerra A, Multhoff G. Hsp70 in Liquid Biopsies-A Tumor-Specific Biomarker for Detection and Response Monitoring in Cancer. Cancers (Basel). 2021 Jul 23;13(15):3706. doi: 10.3390/cancers13153706. PMID: 34359606; PMCID: PMC8345117.

  2. Medenwald D, Fietkau R, Klautke G, Langer S, Würschmidt F, Vordermark D. Trends in radiotherapy inpatient admissions in Germany: a population-based study over a 10-year period. Strahlenther Onkol. 2021 Oct;197(10):865-875. doi: 10.1007/s00066-021-01829-7. Epub 2021 Sep 3. PMID: 34477888; PMCID: PMC8458212.

  3. Efremov L, Abera SF, Bedir A, Vordermark D, Medenwald D. Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from the German Cancer Registries. J Cancer Res Clin Oncol. 2021 Nov;147(11):3381-3390. doi: 10.1007/s00432-021-03596-5. Epub 2021 Mar 20. Erratum in: J Cancer Res Clin Oncol. 2021 Apr 13;: PMID: 33743072; PMCID: PMC8484256.

  4. Mauz-Körholz C, Landman-Parker J, Balwierz W, Ammann RA, Anderson RA, Attarbaschi A, Bartelt JM, Beishuizen A, Boudjemaa S, Cepelova M, Claviez A, Daw S, Dieckmann K, Fernández-Teijeiro A, Fosså A, Gattenlöhner S, Georgi T, Hjalgrim LL, Hraskova A, Karlén J, Kluge R, Kurch L, Leblanc T, Mann G, Montravers F, Pears J, Pelz T, Rajić V, Ramsay AD, Stoevesandt D, Uyttebroeck A, Vordermark D, Körholz D, Hasenclever D, Wallace WH. Response-adapted omission of radiotherapy and comparison of consolidation chemotherapy in children and adolescents with intermediate-stage and advanced-stage classical Hodgkin lymphoma (EuroNet-PHL-C1): a titration study with an open-label, embedded, multinational, non-inferiority, randomised controlled trial. Lancet Oncol. 2021 Dec 9:S1470-2045(21)00470-8. doi: 10.1016/S1470-2045(21)00470-8. Epub ahead of print. PMID: 34895479.

  5. Dapper H, Belka C, Bock F, Budach V, Budach W, Christiansen H, Debus J, Distel L, Dunst J, Eckert F, Eich H, Eicheler W, Engenhart-Cabillic R, Fietkau R, Fleischmann DF, Frerker B, Giordano FA, Grosu AL, Herfarth K, Hildebrandt G, Kaul D, Kölbl O, Krause M, Krug D, Martin D, Matuschek C, Medenwald D, Nicolay NH, Niewald M, Oertel M, Petersen C, Pohl F, Raabe A, Rödel C, Rübe C, Schmalz C, Schmeel LC, Steinmann D, Stüben G, Thamm R, Vordermark D, Vorwerk H, Wiegel T, Zips D, Combs SE. Integration of radiation oncology teaching in medical studies by German medical faculties due to the new licensing regulations : An overview and recommendations of the consortium academic radiation oncology of the German Society for Radiation Oncology (DEGRO). Strahlenther Onkol. 2021 Nov 16:1–10. doi: 10.1007/s00066-021-01861-7. Epub ahead of print. PMID: 34786605.

  6. Sztankay, M., Wintner, L.M., Roggendorf, S. et al. Developing an e-learning course on the use of PRO measures in oncological practice: health care professionals’ preferences for learning content and methods. Support Care Cancer (2021). doi: 10.1007/s00520-021-06676-x. PMID: 34797424

  7. Beckmann MW, Stuebs FA, Vordermark D, Koch MC, Horn LC, Fehm T: Clinical practice guideline: The diagnosis, treatment, and aftercare of cervical carcinoma. Dtsch Arztebl Int 2021; 118: 806–12. doi: 10.3238/arztebl.m2021.0352. PMID: 34755595

  8. Sodergren SC, Wheelwright SJ, Fitzsimmons D, Efficace F, Sprangers M, Fayers P, Harle A, Schmidt H, Bottomley A, Darlington AS, Benson C, Bredart A, Hentschel L, Arraras JI, Ioannidis G, Leahy M, Lugowska I, Nicolatou-Galitis O, Petranovic D, Rohde GE, Vassiliou V, Johnson CD. EORTC Quality of Life Group. Developing Symptom Lists for People with Cancer Treated with Targeted Therapies. Target Oncol. 2021 Jan;16(1):95-107. doi: 10.1007/s11523-020-00769-z . PMID: 33165751.

  9. Koller M, Müller K, Nolte S, Schmidt H, Harvey C, Mölle U, Boehm A, Engeler D, Metzger J, Sztankay M, Holzner B, Groenvold M, Kuliś D, Bottomley A; EORTC Quality of Life Group. Investigating the response scale of the EORTC QLQ-C30 in German cancer patients and a population survey. Health Qual Life Outcomes. 2021 Oct 9;19(1):235. doi: 10.1186/s12955-021-01866-x. PMID: 34625074.

  10. Sommerlatte S, Schmidt H, Vordermark D, Schildmann J. Decision Making in Geriatric Oncology: Supported Versus Assisted Decision Making. J Clin Oncol 2021 Sep 17;JCO2101643. Online ahead of print. doi: 10.1200/JCO.21.01643. PMID: 34533975.

  11. Medenwald D, Schmidt-Pokrzywniak A, Kapsner LA, Buttmann-Schweiger N, Hopff S, Schmidt H, Vordermark D. Onkologische Versorgungsforschung in Deutschland - Neue Perspektiven durch Vernetzung. Forum (2021). doi: 10.1007/s12312-021-00996-z.

  12. Rahne T, Plontke SK, Vordermark D, Strauss C, Scheller C. Hörklassen bei Patienten mit Vestibularisschwannom bei Verwendung deutschsprachiger Testverfahren. HNO 69, 750–758 (2021). doi: 10.1007/s00106-020-00948-4.

  13. Medenwald D, Fietkau R, Klautke G, Langer S, Würschmidt F, Vordermark D. Trends in radiotherapy inpatient admissions in Germany: a population-based study over a 10-year period. Strahlenther Onkol. 2021 Sep 3. doi: 10.1007/s00066-021-01829-7. Epub ahead of print. PMID: 34477888.

  14. Greither T, Steiner T, Bache M, Serrero G, Otto S, Taubert H, Eckert AW, Kappler, M.
    GP88/PGRN Serum Levels Are Associated with Prognosis for Oral Squamous Cell Carcinoma Patients. Biology 2021, 10, 400. DOI: 10.3390/biology10050400. PMID: 34064411.

  15. Wilke L, Moustakis C, Blanck O, Albers D, Albrecht C, Avcu Y, Boucenna R, Buchauer K, Etzelstorfer T, Henkenberens C, Jeller D, Jurianz K, Kornhuber C, Kretschmer M, Lotze S, Meier K, Pemler P, Riegler A, Röser A, Schmidhalter D, Spruijt KH, Surber G, Vallet V, Wiehle R, Willner J, Winkler P, Wittig A, Guckenberger M, Tanadini-Lang S. Improving interinstitutional and intertechnology consistency of pulmonary SBRT by dose prescription to the mean internal target volume dose. Strahlenther Onkol. 2021 Sep;197(9):836-846. doi: 10.1007/s00066-021-01799-w. Epub 2021 Jul 1. DOI: 10.1007/s00066-021-01799-w. PMID: 34196725

  16. Güttler A, Eiselt Y, Funtan A, Thiel A, Petrenko M, Keßler J, Thondorf I, Paschke R, Vordermark D, Bache M. Betulin Sulfonamides as Carbonic Anhydrase Inhibitors and Anticancer Agents in Breast Cancer Cells. Int J Mol Sci. 2021 Aug 16;22(16):8808. doi: 10.3390/ijms22168808. PMID: 34445506

  17. Petrenko M, Güttler A, Pflüger, E, Serbian I, Kahnt, M, Eiselt Y, Keßler J, Funtan A, Paschke R, Csuk R, Vordermark D, Bache M. MSBA-S - A pentacyclic sulfamate as a new option for radiotherapy of human breast cancer cells. Eur J Med Chem. 2021 Jul 28;224:113721. doi: 10.1016/j.ejmech.2021.113721. Online ahead of print. PMID: 34365127

  18. Werner C, Stangl S, Salvermoser L, Schwab M, Shevtsov M, Xanthopoulos A, Wang F, Dezfouli AB, Thölke D, Ostheimer C, Medenwald D, Windberg M, Bache M, Schlapschy M, Skerra A, Multhoff G. Hsp70 in Liquid Biopsies-A Tumor-Specific Biomarker for Detection and Response Monitoring in Cancer. Cancers (Basel). 2021 Jul 23;13(15):3706. doi: 10.3390/cancers13153706. PMID: 34359606.

  19. Gutzmer, R., Rose, C., Vordermark, D. et al. Aktueller Stand bei nichtmelanozytären Hauttumoren. Onkologe 27, 524 (2021). doi:10.1007/s00761-021-00953-4

  20. Schmidt H, Nordhausen T, Lampe K , Stegmann S, Vordermark D. Multimorbide ältere Tumorpatient*innen: Therapieplanung und Lebensqualität. Forum 36, 224–233 (2021). doi:10.1007/s12312-021-00934-z

  21. Lo AC, Dieckmann K, Pelz T, Gallop-Evans E, Engenhart-Cabillic R, Vordermark D, Kelly KM, Schwartz CL, Constine LS, Roberts K, Hodgson D. Pediatric classical Hodgkin lymphoma. Pediatr Blood Cancer 2021 May;68 Suppl 2:e28562. doi: 10.1002/pbc.28562. PMID: 33818890

  22. Flöther L, Pötzsch B, Jung M, Jung R, Bucher M, Glowka A, Medenwald D. Treatment effects of palliative care consultation and patient contentment: A monocentric observational study. Medicine (Baltimore) 2021 Mar 26;100(12):e24320. doi:10.1097/MD.0000000000024320. PMID: 33761631

  23. Vordermark D. Besonderheiten der Strahlentherapie bei nichtmelanozytären Hauttumoren. Onkologe 2021 Mar 2. doi 10.1007/s00761-021-00923-w. PMID: 33754162.

  24. Buergy D, Würschmidt F, Gkika E, Hörner-Rieber J, Knippen S, Gerum S, Balermpas P, Henkenberens C, Voglhuber T, Kornhuber C, Barczyk S, Röper B, Rashid A, Blanck O, Wittig A, Herold HU, Brunner TB, Klement RJ, Kahl KH, Ciernik IF, Ottinger A, Izaguirre V, Putz F, König L, Hoffmann M, Combs SE, Guckenberger M, Boda-Heggemann J. Stereotactic or conformal radiotherapy for adrenal metastases - patient characteristics and outcomes in a multicenter analysis. Int J Cancer. 2021 Mar 8. doi: 10.1002/ijc.33546. PMID: 33682927

  25. Vordermark D. Verschlechterung der Lebensqualität von Patienten mit Morbus Hodgkin in den folgenden 5 Jahren nach abgeschlossener Therapie: Langzeitdaten aus den Studien HD13, HD14 und HD15. Strahlenther Onkol 2021 Mar 22. doi: 10.1007/s00066-021-01755-8. PMID: 33754162

  26. Abera S, Mikolajczyk R, Kantelhardt E, Efremov L, Bedir A, Ostheimer C, Glowka A, Vordermark D, Medenwald D. Lung Cancer Attributed Mortality Among 316,336 Early Stage Breast Cancer Cases Treated by Radiotherapy and/or Chemotherapy, 2000-2015: Evidence From the SEER Database. Front Oncol. 2021 Feb 25;10:602397. doi: 10.3389/fonc.2020.602397. eCollection 2020. PMID: 33718108

  27. Efromov L, Abera S, Bedir A, Vordermark D, Medenwald D. Patterns of glioblastoma treatment and survival over a 16-years period: pooled data from rhe German Cancer Registries. J Cancer Res Clin Oncol. 2021 Mar 20. doi: 10.1007/s00432-021-03596-5. PMID: 33743072

  28. Bedir A, Abera SF, Efremov L, Hassan L, Vordermark D, Medenwald D. Socioeconomic disparities in head and neck cancer survival in Germany: a causal mediation analysis using population-based cancer registry data. J Cancer Res Clin Oncol. 2021 Feb 11. PMID: 33569714.

  29. Kurch L, Mauz-Körholz C, Fosså A, Georgi TW, Kluge R, Bartelt JM, Kunze C, Wohlgemuth WA, Pelz T, Vordermark D, Plößl S, Hasenclever D, Sabri O, Landman-Parker J, Wallace WH, Karlen J, Fernández-Teijeiro A, Cepelova M, Klekawka T, Løndalen AM, Steiner D, Krombach G, Attarbaschi A, Hoffmann M, Ceppi F, Pears J, Hraskova A, Uyttebroeck A, Beishuizen A, Dieckmann K, Leblanc T, Daw S, Körholz D, Stoevesandt D. Assessment of Waldeyer's ring in pediatric and adolescent Hodgkin lymphoma patients-Importance of multimodality imaging: Results from the EuroNet-PHL-C1 trial. Pediatr Blood Cancer. 2021 Feb 3:e28903. doi: 10.1002/pbc.28903. PMID: 33538093

  30. C. Ostheimer MD, M. Mäurer, […] D. Medenwald. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group. Strahlenther Onkol (2021). doi: 10.1007/s00066-020-01727-4. PMID: 33410959

  1. Dietzel C, Vordermark D. Radiogene Pneumonitis: Kalkulierbares Risiko mit moderner Strahlentherapie. Info Pneumologie & Allergologie 2020; 2(4): 6-10.

  2. Lakowa N, Golla A, Lau A, Stoll O, Vordermark D, Jahn P. Bewegungsförderung und Symptombewältigung: Exergames bei Tumorpatienten. Im Fokus Onkologie 2020; 23(1): 36-41.

  3. Medenwald D, Langer S, Gottschick C, Vordermark D. Effect of Radiotherapy in Addition to Surgery in Early Stage Endometrial Cancer: A Population-Based Study.  Cancers (Basel). 2020 Dec 17;12(12):3814. doi: 10.3390/cancers12123814.

  4. Vordermark D, Medenwald D, Izaguirre V, Sieker F, Marnitz S. The Role of Postoperative Radiotherapy for Carcinosarcoma of the Uterus.  Cancers (Basel). 2020 Nov 30;12(12):3573. doi: 10.3390/cancers12123573.

  5. Petrenko M, Güttler A, Funtan A, Keßler J, Emmerich D, Paschke R, Vordermark D, Bache M. Combined 3-O-acetylbetulin treatment and carbonic anhydrase IX inhibition results in additive effects on human breast cancer cells.  Chem Biol Interact. 2021 Jan 5;333:109326. doi: 10.1016/j.cbi.2020.109326. Epub 2020 Nov 25.
  6. Abera Ferede S, Mikolajczyk RT, Kantelhardt E, Efremov L, Bedir A, Ostheimer C, Glowka A, Vordermark D and Medenwald D (2020). Lung Cancer Attributed Mortality Among 316,336 Early Stage Breast Cancer Cases Treated by Radiotherapy and/or Chemotherapy 2000–2015: Evidence From the SEER Database. Front. Oncol. 10:602397. doi: 10.3389/fonc.2020.602397.
  7. Oertel M, Elsayad K, Engenhart-Cabillic R, Reinartz G, Baues C, Schmidberger H, Vordermark D, Marnitz S, Lukas P, Ruebe C, Engert A, Lenz G, Eich HT. Radiation treatment of hemato-oncological patients in times of the COVID-19 pandemic: Expert recommendations from the radiation oncology panels of the German Hodgkin Study Group and the German Lymphoma Alliance. Strahlenther Onkol. 2020 Oct 30:1-7. doi: 10.1007/s00066-020-01705-w. Online ahead of print. PMID: 33125504 Free PMC article. 
  8. Bacher H, Schweyen R, Vordermark D, Leplow B, Hey J. Development and Validation of an Information Leaflet on Oral Care for Irradiated Patients. Patient Prefer Adherence. 2020 Oct 6;14:1791-1799. doi: 10.2147/PPA.S256990. eCollection 2020. PMID: 33116424 Free PMC article. 
  9. Plontke SK, Caye-Thomasen P, Strauss C, Kösling S, Götze G, Siebolts U, Vordermark D, Wagner L, Fröhlich L, Rahne T. Management of transmodiolar and transmacular cochleovestibular schwannomas with and without cochlear implantation. HNO. 2020 Oct 12. doi: 10.1007/s00106-020-00919-9. Online ahead of print. PMID: 33044580 English. 
  10. Rahne T, Plontke SK, Vordermark D, Strauss C, Scheller C. [Hearing classification in patients with vestibular schwannoma using German-language test procedures]. HNO. 2020 Sep 25. doi: 10.1007/s00106-020-00948-4. Online ahead of print. PMID: 32975608 German. 
  11. Plontke SK, Caye-Thomasen P, Strauss C, Kösling S, Götze G, Siebolts U, Vordermark D, Wagner L, Fröhlich L, Rahne T. Management of transmodiolar and transmacular cochleovestibular schwannomas with and without cochlear implantation. German version. HNO 2020 Sep 4. doi: 10.1007/s00106-020-00918-w
  12. Gutzmer R, Vordermark D, Hassel JC, Krex D, Wendl C, Schadendorf D, Sickmann T, Rieken S, Pukrop T, Höller C, Eigentler TK, Meier F. Melanoma brain metastases - Interdisciplinary management recommendations 2020. Cancer Treat Rev. 2020 Sep;89:102083. doi: 10.1016/j.ctrv.2020.102083. Epub 2020 Jul 18 
  13. Vordermark, D, Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups. Radiation Oncology (2020) 15:140. https://doi.org/10.1186/s13014-020-01579-3 
  14. Teichmann T, Salz H, Schwedas M, Schilz J, Wolf U, Walke M, Kornhuber C, Berger R, Schröder D, Hourle M, Peil T, Tümmler H, Wiezorek T, Wittig A. A multi-institutional initiative on patient-related quality assurance: Independent computational dose verification of fluence-modulated treatment techniques. Z Med Phys 30(2)2020, p155-165. https://doi.org/10.1016/j.zemedi.2019.12.003
  15. Oertel M., Linde P., Mäurer M., Fleischmann D.F., Dietzel C.T., Krug D. - Quality of teaching radiation oncology in Germany—where do we stand? Strahlenther Onkol 2020. https://doi.org/10.1007/s00066-020-01623-x
  16. Medenwald D, Ferencz J, Vordermark D. Predictors of the regional variation of prostatectomy or radiotherapy: evidence from German cancer registries. J Cancer Res Clin Oncol (2020). https://doi.org/10.1007/s00432-020-03140-x
  17. Evers C, Ostheimer C, Sieker F, Vordermark D, Medenwald D. Benefit from surgery with additional radiotherapy in N1 head and neck cancer at the time of IMRT: A population-based study on recent developments. PLoS One. 2020 Feb26;15(2):e0229266. doi: 10.1371/journal.pone.0229266. eCollection 2020. PubMed PMID: 32101560.
  18. Medenwald D, Vordermark D, Dietzel C. Early Mortality of Prostatectomy vs. Radiotherapy as a Primary Treatment for Prostate Cancer: A Population-Based Study From the United States and East Germany. Front. Oncol., 17 January 2020, https://doi.org/10.3389/fonc.2019.01451
  19. Kesper C, Viestenz A, Siebolts U, Wickenhauser C, Sieker F, Huth A, Heichel J. [Orbital Amyloidosis - Comparison of Two Different Clinical Courses]. Klin Monbl Augenheilkd. 2020 Jan;237(1):35-40. doi: 10.1055/a-1078-1274. 
  1. Emons G, Tempfer C, Battista MJ, Mustea A, Vordermark D; Uterus Commission of the AGO. Adjuvant Radiotherapy and/or Chemotherapy for Endometrial Cancer, Status as at 2019: Opinion of the Uterus Commission of the Gynecological Oncology Working Group (AGO). Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1273-1277. doi: 10.1055/a-1019-7720.
  2. Denschlag D, Ackermann S, Battista MJ, Cremer W, Egerer G, Follmann M, Haas H, Harter P, Hettmer S, Horn LC, Juhasz-Boess I, Kast K, Köhler G, Kröncke T, Lindel K, Mallmann P, Meyer-Steinacker R, Mustea A, Petru E, Reichardt P, Schmidt D, Strauss HG, Tempfer C, Thiel F, Ulrich U, Vogl T, Vordermark D, Gass P, Beckmann MW. Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019). Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1043-1060. doi: 10.1055/a-0882-4116. 
  3. Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E. Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis. Liver Cancer. 2019 Jul;8(4):281-294.
  4. Andersson P, Ostheimer C. Editorial: Combinatorial Approaches to Enhance Anti-tumor Immunity: Focus on Immune Checkpoint Blockade Therapy. Front Immunol. 2019 Sep 6;10:2083. doi: 10.3389/fimmu.2019.02083. eCollection 2019. No abstract available. 
  5. Bache M, Hein A, Petrenko M, Güttler A, Keßler J, Wichmann H, Kappler M, Emmerich D, Paschke R, Vordermark D. Evaluation of the betulinic Acid-Cisplatin conjugate APC and its precursor DE9B for the treatment of human malignant glioma. Chem Biol Interact. 2019 Oct 2:108841. doi: 10.1016/j.cbi.2019.108841.
  6. Kappler M, Pabst U, Weinholdt C, Taubert H, Rot S, Kaune T, Kotrba J, Porsch M, Güttler A, Bache M, Krohn K, Bull F, Riemann A, Wickenhauser C, Seliger B, Schubert J, Al-Nawas B, Thews O, Grosse I, Vordermark D, Eckert AW. Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism. Int J Mol Sci. 2019 Sep 24;20(19). pii: E4742. doi: 10.3390/ijms20194742.
  7. Ostheimer C, Evers C, Palm F, Mikolajczyk R, Vordermark D, Medenwald D. Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer: a population-based study on recent developments. J Cancer Res Clin Oncol. 2019 Sep 6. doi: 10.1007/s00432-019-03013-y. [Epub ahead of print] PubMed PMID: 31492985.
  8. Lautenschlaeger S, Iancu G, Flatten V, Baumann K, Thiemer M, Dumke C, Zink K, Hauswald H, Vordermark D, Mauz-Körholz C, Engenhart-Cabillic R, Eberle F. Advantage of proton-radiotherapy for pediatric patients and adolescents with Hodgkin's disease. Radiat Oncol. 2019 Sep 2;14(1):157. 
  9. Weinholdt C, Wichmann H, Kotrba J, Ardell DH, Kappler M, Eckert AW, Vordermark D, Grosse I. Prediction of regulatory targets of alternative isoforms of the epidermal growth factor receptor in a glioblastoma cell line. BMC Bioinformatics. 2019 Aug 22;20(1):434. 
  10. Steinmann D, Vordermark D, Gerstenberg W, Aschoff R, Gharbi N, Müller A, Schäfer C, Theodorou M, Wypior HJ, Geinitz H; Quality of Life Working Group of the German Radiation Oncology Society (DEGRO). Quality of life in patients with limited (1-3) brain metastases undergoing stereotactic or whole brain radiotherapy : A prospective study of the DEGRO QoL working group. Strahlenther Onkol. 2019 Aug 15. 
  11. Kessler J, Hohmann T, Güttler A, Petrenko M, Ostheimer C, Hohmann U, Bache M, Dehghani F, Vordermark D. Radiosensitization and a Less Aggressive Phenotype of Human Malignant Glioma Cells Expressing Isocitrate Dehydrogenase 1 (IDH1) Mutant Protein: Dissecting the Mechanisms. Cancers (Basel). 2019 Jun 25;11(6). 
  12. Emons G, Vordermark D. Adjuvant treatment for endometrial cancer. Curr Opin Oncol. 2019 Sep;31(5):404-410.
  13. Janssen S, Fahlbusch FB, Käsmann L, Rades D, Vordermark D. Radiotherapy for prostate cancer: DISCERN quality assessment of patient-oriented websites in 2018. BMC Urol. 2019 May 28;19(1):42. 
  14. Emons G, Steiner E, Vordermark D. Wichtigste Ergebnisse der S3-Leitlinie „Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom“; Best Practice Onkologie 2019;14:114-120. 
  15. Güttler A, Theuerkorn K, Riemann A, Wichmann H, Kessler J, Thews O, Bache M, Vordermark D. Cellular and radiobiological effects of carbonic anhydrase IX in human breast cancer cells. Oncol Rep. 2019 Apr;41(4):2585-2594. doi: 10.3892/or.2019.7001. Epub 2019 Feb 5. 
  16. Rot S, Kaune T, Taubert H, Greither T, Kotrba J, Güttler A, Wichmann H, Bilkenroth U, Wienke A, Al-Nawas B, Bache M, Vordermark D, Wickenhauser C, Bethmann D, Eckert AW, Kappler M. Prognostic impact of mRNA levels of LGR5 transcript variants in OSCC patients. BMC Cancer. 2019 Feb 15;19(1):155. doi: 10.1186/s12885-019-5327-8.
  17. Klement RJ, Abbasi-Senger N, Adebahr S, Alheid H, Allgaeuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Eble MJ, Ernst I, Gerum S, Habermehl D, Hass P, Henkenberens C, Hildebrandt G, Imhoff D, Kahl H, Klass ND, Krempien R, Lewitzki V, Lohaus F, Ostheimer C, Papachristofilou A, Petersen C, Rieber J, Schneider T, Schrade E, Semrau R, Wachter S, Wittig A, Guckenberger M, Andratschke N. The impact of local control on overall survival after stereotactic body radiotherapy for liver and lung metastases from colorectal cancer: a combined analysis of 388 patients with 500 metastases. BMC Cancer. 2019 Feb 26;19(1):173. doi: 10.1186/s12885-019-5362-5.
  18. Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 2: Treatment, Prevention and Follow-up. J Dtsch Dermatol Ges. 2019 Feb;17(2):214-230. doi: 10.1111/ddg.13755.
  19. Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k-Leitlinie Basalzellkarzinom der Haut - Teil 2: Therapie, Prävention und Nachsorge. J Dtsch Dermatol Ges. 2019 Feb;17(2):214-231. doi: 10.1111/ddg.13755_g. No abstract available. 
  20. Eckert AW, Horter S, Bethmann D, Kotrba J, Kaune T, Rot S, Bache M, Bilkenroth U, Reich W, Greither T, Wickenhauser C, Vordermark D, Taubert H, Kappler M. Investigation of the Prognostic Role of Carbonic Anhydrase 9 (CAIX) of the Cellular mRNA/Protein Level or Soluble CAIX Protein in Patients with Oral Squamous Cell Carcinoma. Int J Mol Sci. 2019 Jan 16;20(2). pii: E375. doi: 10.3390/ijms20020375.
  21. Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k-Leitlinie Basalzellkarzinom der Haut - Teil 1: Epidemiologie, Genetik und Diagnostik. J Dtsch Dermatol Ges. 2019 Jan;17(1):94-104. doi: 10.1111/ddg.13733_g. 
  22. Lang BM, Balermpas P, Bauer A, Blum A, Brölsch GF, Dirschka T, Follmann M, Frank J, Frerich B, Fritz K, Hauschild A, Heindl LM, Howaldt HP, Ihrler S, Kakkassery V, Klumpp B, Krause-Bergmann A, Löser C, Meissner M, Sachse MM, Schlaak M, Schön MP, Tischendorf L, Tronnier M, Vordermark D, Welzel J, Weichenthal M, Wiegand S, Kaufmann R, Grabbe S. S2k Guidelines for Cutaneous Basal Cell Carcinoma - Part 1: Epidemiology, Genetics and Diagnosis. J Dtsch Dermatol Ges. 2019 Jan;17(1):94-103. doi: 10.1111/ddg.13733.
  1. Rot S, Taubert H, Bache M, Greither T, Würl P, Holzhausen HJ, Eckert AW, Vordermark D, Kappler M. Low HIF-1α and low EGFR mRNA Expression Significantly Associate with Poor Survival in Soft Tissue Sarcoma Patients; the Proteins React Differently. Int J Mol Sci. 2018 Dec 3;19(12). pii: E3842. doi: 10.3390/ijms19123842.
  2. Emons G, Tempfer C, Battista MJ, Mustea A, Vordermark D. Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study. Geburtshilfe Frauenheilkd. 2018 Oct;78(10):923-926. doi: 10.1055/a-0658-1918. Epub 2018 Oct 19.
  3. Emons G, Steiner E, Vordermark D, Uleer C, Bock N, Paradies K, Ortmann O, Aretz S, Mallmann P, Kurzeder C, Hagen V, van Oorschot B, Höcht S, Feyer P, Egerer G, Friedrich M, Cremer W, Prott FJ, Horn LC, Prömpeler H, Langrehr J, Leinung S, Beckmann MW, Kimmig R, Letsch A, Reinhardt M, Alt-Epping B, Kiesel L, Menke J, Gebhardt M, Steinke-Lange V, Rahner N, Lichtenegger W, Zeimet A, Hanf V, Weis J, Mueller M, Henscher U, Schmutzler RK, Meindl A, Hilpert F, Panke JE, Strnad V, Niehues C, Dauelsberg T, Niehoff P, Mayr D, Grab D, Kreißl M, Witteler R, Schorsch A, Mustea A, Petru E, Hübner J, Rose AD, Wight E, Tholen R, Bauerschmitz GJ, Fleisch M, Juhasz-Boess I, Sigurd L, Runnebaum I, Tempfer C, Nothacker MJ, Blödt S, Follmann M, Langer T, Raatz H, Wesselmann S, Erdogan S. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Nummer 032/034-OL, April 2018) - Part 1 with Recommendations on the Epidemiology, Screening, Diagnosis and Hereditary Factors of Endometrial Cancer. Geburtshilfe Frauenheilkd. 2018 Oct;78(10):949-971. doi: 10.1055/a-0713-1218. Epub 2018 Oct 19.
  4. Schmidt H, Nordhausen T, Boese S, Vordermark D, Wheelwright S, Wienke A, Johnson CD.Factors Influencing Global Health Related Quality of Life in Elderly Cancer Patients: Results of a Secondary Data Analysis. Geriatrics (Basel) 2018;3:E5.
  5. Bock N, Vordermark D, Emons G. Endometriumkarzinom: Eine Übersicht mit aktuellen Aspekten. Onkologe 2018;24:177-88
  6. Mallmann P, Höcht S, Vordermark D, Zeimet AG, Petru E,·Feyer P, Letsch A, Hagen V. Adjuvante Therapie des Endometriumkarzinoms. Gynäkologe 2018; 51:1032–1036
  7. Wösle M, Krause L, Sreenivasa S, Vordermark D, Ciernik IF. Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™ : Physics and technique of linac-based photon beam therapy. Strahlenther Onkol. 2018 Oct;194(10):929-943. doi: 10.1007/s00066-018-1349-4. Epub 2018 Aug 16. 
  8. Andratschke N, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Guckenberger M, Hildebrandt G, Klement RJ, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Habermehl D. The SBRT database initiative of the German Society for Radiation Oncology (DEGRO): patterns of care and outcome analysis of stereotactic body radiotherapy (SBRT) for liver oligometastases in 474 patients with 623 metastases. BMC Cancer. 2018 Mar 13;18(1):283. doi: 10.1186/s12885-018-4191-2. 
  9. Medenwald D, Vordermark D, Dietzel CT. Number of radiotherapy treatment machines in the population and cancer mortality: an ecological study. Clin. Epidemiol. 2018 Sep 21;10:1249-1273. doi: 10.2147/CLEP.S156764. eCollection 2018. PubMed PMID: 30288122; PubMed Central PMCID: PMC6163015. 
  10. Medenwald D, Dietzel CT, Vordermark D. Health services research in German radiation oncology: new opportunities to advance cancer care. Strahlenther Onkol. 2018 Sep 4. doi: 10.1007/s00066-018-1357-4. [Epub ahead of print] Review. PubMed PMID: 30182245.
  11. Dietzel CT, Jablonska K, Niyazi M, Gauer T, Ebert N, Ostheimer C, Krug D. Quality of training in radiation oncology in Germany: where do we stand? Results from a 2016/2017 survey performed by the working group "young DEGRO" of the German society of radiation oncology (DEGRO). Strahlenther Onkol. 2018 Jan 18. doi: 10.1007/s00066-017-1250-6. [Epub ahead of print].
  12. Fiedler E, Vordermark D. Outcome of Combined Treatment of Surgery and Adjuvant Radiotherapy in Merkel Cell Carcinoma. Acta Derm Venereol. 2018 Jan 30. doi: 10.2340/00015555-2895. [Epub ahead of print].
  13. Vanchanagiri K, Emmerich D, Bruschke M, Bache M, Seifert F, Csuk R, Vordermark D, Paschke R. Synthesis and biological investigation of new carbonic anhydrase IX (CAIX inhibitors). Chem Biol Interact. 2018 Feb 15. pii: S0009-2797(17)31101-8. doi: 10.1016/j.cbi.2018.02.014. [Epub ahead of print].
  14. Göttgens EL, Ostheimer C, Bussink J, Span PN and Hammond EM. HPV, hypoxia and radiation response in head and neck cancer. Br J Radiol 2018 Mar 1: 20180047 [Epub ahead of print].
  15. Ostheimer C, Evers C, Bache M, Reese T, Vordermark D. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume. Strahlenther Onkol 2018 Jan 16. doi: 10.1007/s00066-017-1255-1. [Epub ahead of print]. 
  1. Schmidt H, Boese S, Lampe K, Jordan K, Fiedler E, Müller-Werdan U, Wienke A, Vordermark D. Erratum to "Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG)" [J Geriatr Oncol 8 (2017) 262-270]. J Geriatr Oncol. 2017 Nov 23. pii: S1879-4068(17)30240-0. doi: 10.1016/j.jgo.2017.11.002. [Epub ahead of print] No abstract available.
  2. Hohmann T, Kessler J, Grabiec U, Bache M, Vordermark D, Dehghani F. Automatic detection of DNA double strand breaks after irradiation using an γH2AX assay. Histol Histopathol. 2017 Nov 15:11945. doi: 10.14670/HH-11-945. [Epub ahead of print]
  3. Kappler M, Kotrba J, Kaune T, Bache M, Rot S, Bethmann D, Wichmann H, Güttler A, Bilkenroth U, Horter S, Gallwitz L, Keßler J, Greither T, Taubert H, Eckert AW, Vordermark D. P4HA1: A single-gene surrogate of hypoxia signatures in oral squamous cell carcinoma patients. Clin Translat Radiat Oncol 5 (2017) 6–11.
  4. Hohmann T, Grabiec U, Vogel C, Ghadban C, Ensminger S, Bache M, Vordermark D, Dehghani F. The Impact of Non-Lethal Single-Dose Radiation on Tumor Invasion and Cytoskeletal Properties. Int J Mol Sci. 2017 Sep 18;18(9). pii: E2001. doi: 10.3390/ijms18092001.
  5. Stoppel G et al. Lung toxicity after radiation in childhood: Results of the International Project on Prospective Analysis of Radiotoxicity in Childhood and Adolescence. Radiother Oncol. 2017 Nov;125(2):286-292. doi: 10.1016/j.radonc.2017.09.026. Epub 2017 Oct 16.
  6. Ostheimer C, Gunther S, Bache M, Vordermark, Multhoff G. Dynamics of heat shock protein 70 serum levels as a predictor of clinical response in non-small-cell lung cancer and correlation with the hypoxia-related marker osteopontin. Front Immunol. 2017 Oct 18;8:1305. doi: 10.3389/fimmu.2017.01305. eCollection 2017.
  7. Käsmann L, Niyazi M, Blanck O, Baues C, Baumann R, Dobiasch S, Eze C, Fleischmann D, Gauer T, Giordano F, Goy Y, Hausmann J, Henkenberens C, Kaul D, Klook L, Krug D, Mäurer M, Panje CM, Rosenbrock J, Sautter L, Schmitt D, Süß C, Thieme AH, Trommer-Nestler M, Ziegler S, Ebert N, Medenwald D, Ostheimer C; Young DEGRO Trial Group. Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer (NSCLC) - a systematic review. Strahlenther Onkol. 2017 Oct 13. doi: 10.1007/s00066-017-1221-y. [Epub ahead of print] 
  8. Kornhuber C, Homonnay N, Lange F, Gerlach R, Vordermark D. Gynecological brachytherapy with Elekta microSelectron V3 afterloading system - A method for determination of actual dwell positions in CT/MR ring applicators. Current Directions in Biomedical Engineering 2017; 3(2): 651–654. doi: 10.1515/cdbme-2017-01
  9. Schaks M, Zähle J, Janich M, Hübsch P, Homonnay N, Gerlach R. Comparative investigation of beam quality index on flattening filter and flattening filter free 6 and 15MV photon beams of an medical linear accelerator. Current Directions in Biomedical Engineering 2017; 3(2): 287-290. doi: 10.1515/cdbme-2017-0059.
  10. Riemann A, Güttler A, Haupt V, Wichmann H, Reime S, Bache M, Vordermark D, Thews O. Inhibition of Carbonic Anhydrase IX by Ureidosulfonamide Inhibitor U104 Reduces Prostate Cancer Cell Growth, But Does not Modulate Daunorubicin or Cisplatin Cytotoxicity. Oncol Res. 2017 Jun 19. doi: 10.3727/096504017X14965111926391. [Epub ahead of print]
  11. Bitterlich C, Vordermark D. Analysis of health-related quality of life in patients with brain tumors prior and subsequent to radiotherapy. Oncol Lett. 2017 Aug;14(2):1841-1846. doi: 10.3892/ol.2017.6310. Epub 2017 Jun 6.
  12. Janssen S, Käsmann L, Fahlbusch FB, Rades D, Vordermark D. Side effects of radiotherapy in breast cancer patients. Strahlenther Onkol. 2017 Aug 30. doi: 10.1007/s00066-017-1197-7. [Epub ahead of print]
  13. Moustakis C, Blanck O, Ebrahimi Tazehmahalleh F, Ka Heng Chan M, Ernst I, Krieger T, Duma MN, Oechsner M, Ganswindt U, Heinz C, Alheit H, Blank H, Nestle U, Wiehle R, Kornhuber C, Ostheimer C, Petersen C, Pollul G, Baus W, Altenstein G, Beckers E, Jurianz K, Sterzing F, Kretschmer M, Seegenschmiedt H, Maass T, Droege S, Wolf U, Schoeffler J, Haverkamp U, Eich HT, Guckenberger M. Planning benchmark study for SBRT of early stage NSCLC : Results of the DEGRO Working Group Stereotactic Radiotherapy. Strahlenther Onkol. 2017 May 31. doi: 10.1007/s00066-017-1151-8.
  14. Simmermacher S, Vordermark D, Kegel T, Strauss C. Malignization of a vestibular schwannoma 13 years after radiation therapy. HNO. 2017 Sep;65(9):766-770. doi: 10.1007/s00106-016-0321-9. German.
  15. Ostheimer C, Baues C, Baumann R, Blanck O, Dobiasch S, Chukwuka E, Ebert N, Fleischmann D, Gauer T, Giordano F, Goy Y, Hausmann J, Henkenberens C, Kaul D, Käsmann L, Klook L, Krug D, Mäurer M, Medenwald D, Niyazi M, Panje C, Rosenbrock J, Sautter L, Schmitt D, Süß C, Thieme A, Trommer-Nestler M, Ziegler S; young DEGRO Trial Group. Tumorvolumenveränderungen in der definitiven Radiochemotherapie des fortgeschrittenen nicht-kleinzelligen Bronchialkarzinoms. FORUM 2017, 32:251-252.
  16. Schmidt H, Boese S, Lampe K, Jordan K, Fiedler E, Müller-Werdan U, Wienke A, Vordermark D. Trans sectoral care of geriatric cancer patients based on comprehensive geriatric assessment and patient-reported quality of life - Results of a multicenter study to develop and pilot test a patient-centered interdisciplinary care concept for geriatric oncology patients (PIVOG). J Geriatr Oncol. 2017 Jul;8(4):262-270. doi: 10.1016/j.jgo.2017.04.002. Epub 2017 May 19.
  17. Medenwald C, Ostheimer C, Trial Group der jungen DEGRO (jDEGRO). Erste deutschlandweite multizentrische Studie der Nachwuchsgruppe der deutschen Gesellschaft für Radioonkologie (DEGRO) startet. Ärzteblatt Sachsen Anhalt, 5/2017: 28.
  18. Mäurer M, Ostheimer C. Erste deutschlandweite multizentrische Studie der Nachwuchsgruppe der Deutschen Gesellschaft für Radioonkologie (jDEGRO) startet. Äezteblatt Thüringen, 4/2017:206. 
  19. Klement RJ, Guckenberger M, Alheid H, Allgäuer M, Becker G, Blanck O, Boda-Heggemann J, Brunner T, Duma M, Gerum S, Habermehl D, Hildebrandt G, Lewitzki V, Ostheimer C, Papachristofilou A, Petersen C, Schneider T, Semrau R, Wachter S, Andratschke N. Stereotactic body radiotherapy for oligo-metastatic liver disease - Influence of pre-treatment chemotherapy and histology on local tumor control. Radiother Oncol. 2017 Mar 5. pii: S0167-8140(17)30038-5. doi: 
  20. Dietzel CT, Schäfer C, Vordermark D. Successful treatment of chronic recurrent multifocal osteomyelitis using low-dose radiotherapy : A case report. Strahlenther Onkol. 2017 Mar;193(3):229-233. 
  21. Medenwald D, Vordermark D, Dietzel CT. Cancer mortality in former East and West Germany: a story of unification? BMC Cancer. 2017 Feb 2;17(1):94. doi: 10.1186/s12885-017-3086-y.
  22. Simmermacher S, Vordermark D, Kegel T, Strauss C. Malignization of vestibular schwannoma 13 years after radiation therapy. HNO. 2017 Jan 5. doi: 10.1007/s00106-016-0321-9. [Epub ahead of print]
  23. Polat B, Kaiser P, Wohlleben G, Gehrke T, Scherzad A, Scheich M, Malzahn U, Fischer T, Vordermark D, Flentje M. Perioperative changes in osteopontin and TGFβ1 plasma levels and their prognostic impact for radiotherapy in head and neck cancer. BMC Cancer. 2017 Jan 3;17(1):6. 
  1. Keßler J, Rot S, Bache M, Kappler M, Würl P, Vordermark D, Taubert H, Greither T. miR-199a-5p regulates HIF-1α and OSGIN2 and its expression is correlated to soft-tissue sarcoma patients' outcome. Oncol Lett. 2016 Dec;12(6):5281-5288. doi: 10.3892/ol.2016.5320.
  2. Ostheimer C, Hübsch P, Janich M, Gerlach R, Vordermark D. Dosimetric comparison of intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) in total scalp irradiation: a single institutional experience. Radiat Oncol J. 2016 Dec;34(4):313-321. 
  3. Ostheimer C, Schweyer F, Reese T, Bache M, Vordermark D. The relationship between tumor volume changes and serial plasma osteopontin detection during radical radiotherapy of non-small-cell lung cancer. Oncol Lett 12: 3449-3456, 2016.
  4. Renner SK, Vordermark D, Beckmann MW. Aktuelle interdisziplinäre Aspekte zur primären Therapie des Zervixkarzinoms. Best Practice Onkologie 2016, 11(5):44-52.
  5. Höcht S, Vordermark D. Adjuvante Strahlentherapie beim Endometriumkarzinom. Onkologe 2016. DOI 10.1007/s00761-016-0148-8.
  6. Vordermark. Radiotherapy of Cervical Cancer. Oncol Res Treat. 2016;39(9):516-20. doi: 10.1159/000448902. Epub 2016 Aug 18. 
  7. Vordermark D, Pelz T. Coronary Heart Disease After Mediastinal Radiotherapy for Hodgkin Lymphoma: Can Risk Calculations From Historic Cohorts Be Used Today? J Clin Oncol. 2016 Aug 20;34(24):2939-40. doi: 10.1200/JCO.2015.65.8286. Epub 2016 May 2. 
  8. Kuhnt T, Stang A, Wienke A, Vordermark D, Schweyen R, Hey J. Potential risk factors for jaw osteoradionecrosis after radiotherapy for head and neck cancer. Radiat Oncol. 2016 Jul 30;11:101. doi: 10.1186/s13014-016-0679-6.
  9. Gnanapragassam VS, Bork K, Galuska CE, Galuska SP, Glanz D, Nagasundaram M, Bache M, Vordermark D, Kohla G, Kannicht C, Schauer R, Horstkorte R. Correction: Sialic Acid Metabolic Engineering: A Potential Strategy for the Neuroblastoma Therapy. PLoS One. 2016 Apr 19;11(4):e0154289. doi: 10.1371/journal.pone.0154289. eCollection 2016. 
  10. Kühnöl J, Kühnöl C, Vordermark D. Radiotherapy of brain metastases from breastcancer: Treatment results and prognostic factors. Oncology Lett, Mar 2016 [in press]. 
  11. Vordermark D, Horsman MR. Hypoxia as a Biomarker and for Personalized Radiation Oncology. Recent Results Cancer Res. 2016;198:123-42. doi:10.1007/978-3-662-49651-0_6. 
  12. Steineck G, Schmidt H, Alevronta E, Sjöberg F, Bull CM, Vordermark D.Toward Restored Bowel Health in Rectal Cancer Survivors. Semin Radiat Oncol. 2016 Jul;26(3):236-50. doi: 10.1016/j.semradonc.2016.03.002. Epub 2016 Mar 18. 
  13. Kappler M, Pabst U, Rot S, Taubert H, Wichmann H, Schubert J, Bache M, Weinholdt C, Immel UD, Grosse I, Vordermark D, Eckert AW. Normoxic accumulation of HIF1α is associated with glutaminolysis. Clin Oral Investig. 2016 Mar 9. [Epub ahead of print] 
  14. Arne Conrad, Petra Feyer, Ulrike Höller, Claudia Hörl, Monika Panzer, Dorothea Riesenbeck, Diana Steinmann, Christof Schäfer, Dirk Vordermark for the DEGRO Quality of Life Group. Patient information in radiation oncology: a German multi-Center cross-sectional study using the EORTC QLQ-INFO26 module. Strahlenther Onkol 2016; 192 (1).
  1. Gunther S, Ostheimer C, Specht A, Erl J, Breuninger S, Combs S, Multhoff G. Development of a novel LipHsp70 ELISA for screening of exosomal Hsp70 in the blood of NSCLC patients. Strahlenther Onkol 2015, Suppl 1;191:S72. 
  2. Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW. Erratum: Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd. 2015 Oct;75(10):e3. 
  3. Bauer A, Vordermark D, Seufferlein T, Schmoll HJ, Dralle H, Mau W, Unverzagt S, Boese S, Fach EM, Landenberger M. Trans-sectoral care in patients with colorectal cancer: Protocol of the randomized controlled multi-center trial Supportive Cancer Care Networkers (SCAN). BMC Cancer. 2015 Dec 22;15:997. doi 10.1186/s12885-015-2002-6.
  4. Schmidt H, Merkel D, Koehler M, Flechtner HH, Sigle J, Klinge B, Jordan K, Vordermark D, Landenberger M, Jahn P. PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study. Support Care Cancer. 2015 Dec 16. [Epub ahead of print]
  5. Denschlag D, Thiel FC, Ackermann S, Harter P, Juhasz-Boess I, Mallmann P, Strauss HG, Ulrich U, Horn LC, Schmidt D, Vordermark D, Vogl T, Reichardt P, Gaß P, Gebhardt M, Beckmann MW. Sarcoma of the Uterus. Guideline of the DGGG (S2k-Level, AWMF Registry No. 015/074, August 2015). Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1028-1042.
  6. Gunther S*, Ostheimer C*, Stangl S, Specht HM; Mozes P, Jesinghaus M, Vordermark D, Combs SE, Peltz F, Jung MP, Multhoff G. Correlation of HSP70 Serum Levels with Gross Tumor Volume and Composition of Lymphocyte Subpopulations in Patients with Squamous Cell and Adeno Non-Small Cell Lung Cancer. Front Immunol. 2015 Nov 2;6:556. eCollection 2015. 
  7. Bache M, Münch C, Güttler A, Wichmann H, Theuerkorn K, Emmerich D, Paschke R, Vordermark D. Betulinyl Sulfamates as Anticancer Agents and Radiosensitizers in Human Breast Cancer Cells. Int J Mol Sci. 2015 Nov 3;16(11):26249-62. doi.10.3390/ijms161125953. 
  8. Ostheimer C, Sudmann J. Die junge DEGRO (jDEGRO) - Fortschritt durch Nachwuchs. FORUM. 2015 Oct;30(5):394-396. DOI 10.007/s12321-015-1377-2.
  9. Mauz-Körholz C, Lange T, Hasenclever D, Burkhardt B, Feller AC, Dörffel W, Kluge R, Vordermark D, Körholz D. Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group. Klin Padiatr. 2015 Sep 10. [Epub ahead of print]. 
  10. Kessler J, Güttler A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D. IDH1(R132H) mutation causes a less aggressive phenotype and radiosensitizes human malignant glioma cells independent of oxygenation status. Radiother Oncol. 2015 Sep;116(3):381-7. doi: 10.1016/j.radonc.2015.08.007. Epud 2015 Aug 29. 
  11. Wohlleben G, Scherzad A, Güttler A, Vordermark D, Kuger S, Flentje M, Polat B. Influence of hypoxia and irradiation on osteopontin expression in head and neck cancer and glioblastoma cell lines. Radiat Oncol. 2015 Aug 12;10;167. doi: 10.1186/s13014-015-0473-x.
  12. Schweyen R, Hey J, Seidel J, Wienke A, Paelecke-Habermann Y, Vordermark D, Kuhnt T. Impact of parotid glanbd dose and patient-related factors on radiation damage to dental hard tissues. J Dent Sci. 2015 Jul 7;10;3:263-269.
  13. Jahn F, Riesner A, Jahn P, Sieker F, Vordermark D, Jordan K. Addition of the Neurokinin-1-Receptor Antagonist (RA) Aprepitant to a 5-Hydroxytryptamin-RA in the Prophylaxis of Nausea and Vomiting Due to Radiation Therapy With Concomittant Cisplatin. Int J Radiat Oncol Biol Phys. 2015 Apr 28. pii: S0360-3016(15)00441-1. doi: 10.1016/k.ijrobp.2015.04.037. [Epub ahead of print].
  14. Bache M, Rot S, Keßler J, Güttler A, Wichman H, Greither T, Wach S, Taubert H, Söling A, Bilkenroth U, Kappler M, Vordermark D. mRNA expression levels of hypoxia-induced stem cell-associated genes in human glioblastoma. Oncol Rep. 2015, 33:3155-3161. doi: 10.3892/or.2015.3932. Epub 2015 Apr 27.
  15. Wedding U, Vordermark D. Lebensqualität alter Patienten mit Krebserkrankungen. Onkologe 2015. DOI 10.1007/s00761-014.2827-7.
  16. Ostheimer C, Bormann C, Fiedler E, Marsch W, Vordermark D. Malignant melanoma brain metastasis: Treatment results and prognostic factors - a single-center retrospective study. Int J Oncol. 2015 Apr 20. doi:10.3892/ijo.2015.2970. [Epub ahead of print].
  17. Steins MB, Vordermark D. Lungenkarzinom. Onkologe 2015. DOI 10.1007/s00761-014-2832-x.
  18. Güttler A, Münch C, Theuerkorn K, Wichmann H, Paschke R, Bache M, Vordermark D. Betulinsäure basierte Carboanhydraseinhibitoren in Kopf-Hals-Tumorzellinien. Exp Strahlenther Klin Strahlenbiol. 2015, 24:146.
  19. Keßler J, Wichmann H, Güttler A, Rot S, Bache M, Vordermark D. Radiosensitivierung von IDH1 R132H-positiven malignen Gliomzellinien unter normoxischen und hypoxischen Bedingungen. Exp Strahlenther Klin Strahlenbiol. 2015, 24:90-94
  20. Bache M, Münch C, Wichmann H, Güttler A, Theuerkorn K, Paschke R, Vordermark D. Betulinylsulfamate in Kombination mit einer Bestrahlung in MDA.MB231-Zellen. Exp Strahlenther Klin Strahlenbiol. 2005, 24:45-46.
  21. Theurkorn K, Güttler A, Thews O, Bache M, Vordermark D. Wirkung des Carboanhydrase IX (CAIX) Inhibitors U104 an humanen Tumorzellen in Abhängigkeit vom O2-Gehalt bzw. pH-Wert. Exp Strahlenther Klin Strahlenbiol. 2015, 24:31-36.
  22. Ostheimer C, Meyer F, Kornhuber C, Reese T, Vordermark D. What does the General and Abdominal Surgeon Need to Know about Radiotherapy? Aspects of Radiotherapy in General and Abdominal Surgery. Zentralbl Chir. 2015 Feb;140(1):83-93. doi: 10.1055/s-0034-1383338. Epub 2015 Feb 27.
  23. Wedding U, Vordermark D, Germer CT, Höffken K. Der "graue Tsunami" in der Onkologie. Onkologe 2015. DOI 10.1007/s00761-014-2823-y.
  1. Kaufmann A, Schmidt H, Ostheimer C, Landenberger M, Vordermark D. Quality of life in very elderly radiotherapy patients: a prospective pilot study using the EORTC QLQ-ELD14 module. Support Care Cancer. 2014 Dec 6. [Epub ahead of print]
  2. Körholz D, Mauz-Körholz C, Vordermark D, Kluge R, Dieckmann K. Increased Relapse Rates in Early Stage Hodgkin Lymphoma (HL) Patients without Radiotherapy: The German Society of Radiooncology (DEGRO) Advises to Treat All Early Stage HL Patients with Radiotherapy. Klin Padiatr. 2014.Nov;226(6-7):307-8. doi: 10.1055/s-0034-1389928. Epub 2014 Nov 28.
  3. Ostheimer C, Bache M, Güttler A, Reese T, Vordermark D. Prognostic information of serial plasma osteopontin measurement in radiotherapy of non-small-cell lung cancer. BMC Cancer. 2014 Nov 21;14:858. doi: 10.186/1471-2407-14-858.
  4. Bache M, Bernhardt S, Passin S, Wichmann H, Hein A, Zschornak M, Kappler M, Taubert H, Paschke R, Vordermark D. Betulinic Acid Derivates MVX-207 and B10 for Treatment of Glioblastoma - An in Vitro Study of Cytotoxicity and Radiosensitization. Int J Mol Sci. 2014 Oct;15(11):19777-90. doi: 10.3390/ijms151119777.
  5. Ostheimer C, Hübsch P, Reese T, Vordermark D. Aktuelle strahlentherapeutische Aspekte in der Behandlung des nicht-kleinzelligen Bronchialkarzinoms. J Onkol. 2014; 7:482-489.
  6. Vordermark D. Stereotactic Body Radiation Therapy for Prostate Cancer: The Need to Assess Patient-Reported Outcomes. J Clin Oncol. 2014 Oct 20;32(30):3456. doi 10.1200/JCO.2014.56.2215. Epub 2014 Sep 2.
  7. Wichmann H, Güttler A, Bache M, Taubert H, Rot S, Kessler J, Eckert AW, Kappler M, Vordermark D. Targeting of EGFR and HER2 with therapeutic antibodies and siRNA: A comparative study in glioblastoma cells. Strahlenther Onkol 2014 Auf 27 [Epub ahead of print]
  8. Gnanapragassam VS, Bork K, Galuska CE, Galuska SP, Glanz D, Nagasundaram M, Bache M, Vordermark D, Kohla G, Kannicht C, Schauer C, Horstkorte R. Sialic Acid metabolic engineerin: a potential strategy for the neuroblastoma therapy. PLoS One 2014 Aug 22;9(8):e105403. doi:10.1371/journal.pone0105403. eCollection 2014.
  9. Kantelhardt EJ, Moelle U, Begoinh M, Addissie A, Trocchi P, Yonas B, Hezkiel P, Stang A, Thomssen C, Vordermark D, Gemechu T, Gebrehiwot Y, Wondemagegnehu T, Aynalem A, Mathewos A. Cervical cancer in ethiopia: survival if 1,059 patients who received oncologic therapy. Oncologist. 2014 Jul;19(7):727-34. doi: 10.1634/theoncologist.2013-0326. Epub 2014 Jun 20.
  10. Dumke AK, Pelz T, Vordermark D: Long-term results of radiotherapy in anaplastic thyroid cancer. Radiat Oncol. 2014 Mar 31;9(1):90. 
  11. Ostheimer C, Janich M, Hübsch P, Gerlach R, Vordermark D: The treatment of extensive scalp lesions using coplanar and non-coplanar photon IMRT: a single institution experience. Radiat Oncol. 2014 Mar 24;9:82. 
  12. Schlitt A, Jordan K, Vordermark D, Schwamborn JR, Langer T, Thomssen C: Cardiotoxicity and oncological treatments. Dtsch Arztebl Int. 2014 Mar 7;111(10):161-8. 
  13. Wichmann H, Güttler A, Bache M, Taubert H, Vetter M, Würl P, Holzhausen HJ, Eckert AW, Kappler M, Vordermark D: Inverse prognostic impact of ErbB2 mRNA and protein expression level in tumors of soft tissue sarcoma patients. Strahlenther Onkol. 2014 Apr 9. [Epub ahead of print]
  14. Wichman H, Güttler A, Bache M, Taubert H, Rot S, Kessler J, Eckert A, Kappler M und Vordermark D. EGFR and Her2: Comparing antibody and siRNA targeting in glioblastoma cells. Exp Strahlenther Klin Strahlenbiol. 2014, 23:26-30.
  15. Bache M, Rot S, Keßler J, Güttler A, Wichmann H, Greither T, Taubert H, Söling A, Bilkenroth U, Kappler M und Vordermark D. mRNA expression levels of hypoxia-induced and stem cell-associated genes in human glioblastoma. Exp Strahlenther Klin Strahlenbiol. 2014, 23:70-4.
  16. Theuerkorn A, Güttler A, Thews O, Bache M und Vordermark D. Targeting von Carboanhydrase IX (CAIX) in Kombination mit Strahlentherapie humaner Tumorzellen. Exp Strahlenther Klin Strahlenbiol. 2014, 23:41-5.
  17. Hein A, Bernhardt S, Passi S, Zschornak M, Paschke R, Bache M und Vordermark D. Molekulare und strahlenbiologische Untersuchungen der Bedeutung von Abkömmlingen der Betulinsäure in Glioblastomzelllinien. Exp Strahlenther Klin Strahlenbiol. 2014, 23:12-6.
  18. Ostheimer C, Bache M, Güttler A, Kotzsch M, Vordermark D. A pilot study on potential plasma hypoxia markers in the radiotherapy of non-small cell lung cancer: Osteopontin, carbonic anhydrase IX and vascular endothelial growth factor. Strahlenther Oncol. 2014 Mar;190(3):276-82. doi: 10.1007/s00066-013-0484-1. Epub 2013 Dec 11.
  1. Wichmann H, Güttler A, Kessler J, Rot S, Bache M, Vordermark D, Kappler M und Eckert A. Bedeutung von EGFR, seiner Spleißvarianten und Her2 in verschiedenen Glioblastomzelllinien. Exp Strahlenther Klin Strahlenbiol. 2013, 22:48-52.
  2. Ostheimer C, Bache M, Hahnel A, Kotzsch M und Vordermark D. Kombinierte Analyse von Osteopontin (OPN) und VEGF, PAI, UPA und UPA-R als potentielle Kandidaten zur Etablierung eines prognostisch-prädiktiven Marker-Panels in der Radiotherapie von Bronchialkarzinomen: erste Daten. Exp Strahlenther Klin Strahlenbiol. 2013, 22:30-5.
  3. Keßler J, Güttler A, Wichmann H, Bache M und Vordermark D. Überexpression von IDH1 R132H und die Strahlenresistenz maligner Gliome. Exp Strahlenther Klin Strahlenbiol. 2013, 22:72-6.
  4. Kappler M, Rot S, Wichmann H, Güttler A, Kessler J, Taubert H, Bache M, Vordermark D und Eckert A. Rolle von HIF1α im normoxischen und hypoxischen Metabolismus. Exp Strahlenther Klin Strahlenbiol. 2013, 22:111-4.
  5. Güttler A, Wichmann H, Keßler J, Ostheimer C, Kappler M, Vordermark D und Bache M. Expressionsanalyse und Lokalisation von Osteopontin und seinen Spleißvarianten in Mamma- und Glioblastomzelllinien. Exp Strahlenther Klin Strahlenbiol. 2013, 22:24-8.
  6. Knäusl B, Lütgendorf-Cauciq C, Hopfgartner J, Dieckmann K, Kurch L, Pelz T, Pötter R, Georg D. Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy? Strahlenther Onkol. 2013, 189:54-61.
  7. Bache M, Bernhardt S, Hein A, Passin S, Zschornak M, Paschke R und Vordermark D. Betulinsäurederivate für die Therapie von Glioblastomen in vitro. Exp Strahlenther Klin Strahlenbiol. 2013, 22:43-7.
  8. Becker JC, Assaf C, Vordermark D, Reske SN, Hense J, Dettenborn T, Seitz O, Grabbe S. Brief S2k guidelines--Merkel cell carcinoma. J Dtsch Dermatol Ges. 2013 Jun;11 Suppl 3:29-36, 31-8.
  9. Dralle H, Musholt TJ, Schabram J, Steinmüller T, Frilling A, Simon D, Goretzki PE, Niederle B, Scheuba C, Clerici T, Hermann M, Kußmann J, Lorenz K, Nies C, Schabram P, Trupka A, Zielke A, Karges W, Luster M, Schmid KW, Vordermark D, Schmoll HJ, Mühlenberg R, Schober O, Rimmele H, Machens A; German Societies of General and Visceral Surgery; Endocrinology; Nuclear Medicine; Pathology; Radiooncology; Oncological Hematology; and the German Thyroid Cancer Patient Support Organization Ohne Schilddrüse leben e.V. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. Langenbecks Arch Surg. 2013 Mar;398(3):347-75.
  10. Güttler A, Giebler M, Cuno P, Wichmann H, Keßler J, Ostheimer C, Söling A, Strauss C, Illert J, Kappler M, Vordermark D, Bache M. Osteopontin and splice variant expression level in human malignant glioma: Radiobiologic effects and prognosis after radiotherapy. Radiother Oncol. 2013 Jul 25.
  11. Müller K, Gnekow A, Falkenstein F, Scheiderbauer J, Zwiener I, Pietsch T, Warmuth-Metz M, Voges J, Nikkhah G, Flentje M, Combs SE, Vordermark D, Kocher M, Kortmann RD. Radiotherapy in pediatric pilocytic astrocytomas : A subgroup analysis within the prospective multicenter study HIT-LGG 1996 by the German Society of Pediatric Oncology and Hematology (GPOH). Strahlenther Onkol. 2013 Aug;189(8):647-655.
  12. Müller K, Schlamann A, Seidel C, Warmuth-Metz M, Christiansen H, Vordermark D, Kortmann RD, Kramm CM, von Bueren AO. Craniospinal irradiation with concurrent temozolomide and nimotuzumab in a child with primary metastatic diffuse intrinsic pontine glioma : A compassionate use treatment. Strahlenther Onkol. 2013 Aug;189(8):693-696.
  13. Oskan F, Kornhuber C, Krause G, Vordermark D. Simultaneous stereotactiv radiation therapy of a primary non-small cell lung cancer and synchrnous carcinoma in situ in a medically inoperabable patient: case report. Radiation Oncology 2013,8:213.
  14. Ostheimer C, Vordermark D: (2013) Osteopontin – an indicator of tumor hypoxia and treatment resistance. In: Vordermark D (Hrsg.), Hypoxia: Causes, Types and Management (255-318). New York: Nova Publishers.
  15. Pflugfelder A, Kochs C, Blum A, Capellaro M, Czeschik C, Dettenborn T, Dill D, Dippel E, Eigentler T, Feyer P, Follmann M, Frerich B, Ganten MK, Gärtner J, Gutzmer R, Hassel J, Hauschild A, Hohenberger P, Hübner J, Kaatz M, Kleeberg UR, Kölbl O, Kortmann RD, Krause-Bergmann A, Kurschat P, Leiter U, Link H, Loquai C, Löser C, Mackensen A, Meier F, Mohr P, Möhrle M, Nashan D, Reske S, Rose C, Sander C, Satzger I, Schiller M, Schlemmer HP, Strittmatter G, Sunderkötter C, Swoboda L, Trefzer U, Voltz R, Vordermark D, Weichenthal M, Werner A, Wesselmann S, Weyergraf AJ, Wick W, Garbe C, Schadendorf D. S3-guideline "diagnosis, therapy and follow-up of melanoma" -- short version. J Dtsch Dermatol Ges. 2013 Jun;11(6):563-602.
  16. Lütgendorf-Cauciq C, Fortina I, Gallop-Evans E, Claude L, Lindh J, Pelz T, Knäusl B, Georg D, Pötter R, Dieckmann K; EuroNet-PHL RT-Group. Multicenter evaluation of different target volume delineation concepts in pediatric Hodgkin's lymphoma. A case study. Strahlenther Onkol. 2012, 188:1025-1030.
  17. Steinbach J, Vordermark D, Gutzmer R. ZNS-Metastasen - eine interdisziplinäre Herausforderung.Onkologie. 2013;36 Suppl 4:2-6.
  18. Steinmann D, Vordermark D, Geinitz H, Aschoff R, Bayerl A, Gerstein J, Hipp M, van Oorschot B, Wypior HJ, Schäfer C: (2013) Proxy assessment of patients before and after radiotherapy for brain metastases : Results of a prospective study using the DEGRO brain module. STRAHLENTHER ONKOL 189(1):47-53. 
  19. Vordermark D (Hrsg.). (2013). Hypoxia: Causes, Types and Management. New York: Nova Publishers.
  20. Vordermark D. Radiation therapy for metastatic non-small-cell lung cancer: when to bring in palliative care? J Clin Oncol. 2013 Jul 20;31(21):2758-9.
  21. Vordermark D. Beeinflusst die Einnahme von Statinen das Behandlungsergebnis der Strahlentherapie beim Prostatakarzinom? Urologe A. 2013 Feb;52(2):264.
  1. Greither T, Koser F, Kappler M, Bache M, Lautenschläger C, Göbel S, Holzhausen HJ, Wach S, Würl P, Taubert H. (2012) Expression of human Piwi-like genes is associated with prognosis for soft tissue sarcoma patients. BMC Cancer. 2012, 12:272.
  2. Hahnel A, Wichmann H, Greither T, Kappler M, Würl P, Kotzsch M, Taubert H, Vordermark D, Bache M: (2012) Prognostic impact of mRNA levels of osteopontin splice variants in soft tissue sarcoma patients. BMC CANCER. 2012, 12:131.
  3. Hahnel A, Giebler M, Wichmann H, Kappler M, Vordermark D, Bache M: (2012) Molekulare und strahlenbiologische Effekte der Inhibierung der OPN-Spleißvarianten in humanen Glioblastomen. EXP STRAHLENTHER KLIN STRAHLENBIOL. 2012, 21:54-8.
  4. Hey J, Seidel J, Schweyen R, Paelecke-Habermann Y, Vordermark D, Gernhardt C, Kuhnt T: (2012) The influence of parotid gland sparing on radiation damages of dental hard tissues. CLIN ORAL INVESTIG. 2012 Oct 5.
  5. Jahn P, Lakowa N, Vordermark D, Stoll O, Landenberger M: (2012) InterACTIV – An Exploratory Study of the Utilization of a Game Console to Promote Physical Activation of Hospitalized Adult Cancer Patients. ONCOL NURS FORUM. 2012, 39:E84-90.
  6. Kappler M, Taubert H, Schubert J, Vordermark D, Eckert AW: (2012) The real face of HIF1α in the tumor process. CELL CYCLE. 2012, 11(21):3932-6.
  7. Kappler M, Wichmann H, Rot S, Hüttelmaier S, Taubert H, Schubert J, Bache M, Vordermark D, Eckert AW: (2012) Expressionsanalyse in der Weichteilsarkomzelllinie SKLMS-1 nach EGF-Stimulation. EXP STRAHLENTHER KLIN STRAHLENBIOL. 2012, 21:119-122.
  8. Keßler J, Hahnel A, Rot S, Bache M, Vordermark D: (2012) Einfluss von IDH1 auf HIF-1α und die Strahlenresistenz maligner Gliome. EXP STRAHLENTHER KLIN STRAHLENBIOL. 2012, 21:59-63.
  9. Kockar F, Yildrim H, Sagkan RI, Hagemann C, Soysal Y, Anacker J, Hamza AA, Vordermark D, Flentje M, Said HM: (2012) Hypoxia and cytokines regulate carbonic anhydrase 9 expression in hepatocellular carcinoma cells in vitro. WORLD J CLIN ONCOL. 2012, 3:82-91.
  10. Oskan F, Vordermark D: (2012) Quality of life after prophylactic cranial irradiation in locally advanced non-small-cell lung cancer. STRAHLENTHER ONKOL. 2012, 188:363-4.
  11. Ostheimer C, Vordermark D: (2012) Osteopontin, a marker of hypoxic radiation resistance? – state of the art, own experiences and critical review of the literature. EXP STRAHLENTHER KLIN STRAHLENBIOL. 2012, 21:43-9
  12. Said HM, Polat B, Stein S, Guckenberger M, Hagemann C, Staab A, Katzer A, Anacker J, Flentje M, Vordermark D: (2012) Inhibition of N-Myc down regulated gene 1 in in vitro cultured human glioblastoma cells. WORLD J CLIN ONCOL 3:104-10.
  13. Schweyen R, Hey J, Fränzel W, Vordermark D, Hildebrandt G, Kuhnt T: (2012) Radiation-related caries: etiology and possible preventive strategies: What should the radiotherapist know? STRAHLENTHER ONKOL. 2012, 188:21-8.
  14. Steinmann D, Paelecke-Habermann Y, Geintiz H, Aschoff R, Bayerl A, Bölling T, Bosch E, Bruns F, Eichenseder-Seiss U, Gerstein J, Gharbi N, Hagg J, Hipp M, Kleff I, Mueller AR, Schaefer C, Schleicher U, Sehlen S, Theodorou M, Wypior HJ, Zehentmayr F, Oorschot B van, Vordermark D: (2012) Prospective evaluation of quality of life effects in patients undergoing palliative radiotherapy for brain metastases. BMC CANCER. 2012, 12:283.
  15. Vordermark D: (2012) Editorial comment. J UROL. 2012, 187:123.
  1. Bache M, Zschornak MP, Passin S, Keßler J, Wichmann H, Kappler M, Paschke R, Kaluđerović GN, Kommera H, Taubert H, Vordermark D: (2011) Increased betulinic acid induced cytotoxicity and radiosensitivity in glioma cells under hypoxic conditions. RADIAT ONCOL 6:111.
  2. Greither T, Würl P, Grochola L, Bond G, Bache M, Kappler M, Lautenschläger C, Holzhausen HJ, Wach S, Eckert AW, Taubert H: (2011) Expression of microRNA 210 associates with poor survival and age of tumor onset of soft-tissue sarcoma patients. INT J CANCER 2011 Mar 31 [Epub ahead of print]
  3. Gutzmer R, Jäger E, Vordermark D: (2011) Adjuvante Therapieansätze in der Onkologie: Eine kritische Nutzen-Risiko-Abwägung. ONKOLOGIE 34(suppl 2):10-12.
  4. Hey J, Setz J, Gerlach R, Janich M, Hildebrandt G, Vordermark D, Gernhardt CR, Kuhnt T: (2011) Parotid gland-recovery after radiotherapy in the head and neck region: 36 months follow-up of a prospective clinical study.RADIAT ONCOL 6:125.
  5. Kappler M, Hanke S, Rot S, Wichmann H, Taubert H, Eckert A, Bache M, Vordermark D: (2011) Rolle des Insulin/EGFR-PI3K/AKT-Survivin-Signalwegs in Tumorzellen – Identifizierung einer Zelllinie mit induzierbarem / intaktem Pathway. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:39-43.
  6. Keschke CB, Kappler M, Taubert H, Bache M, Schubert J, Vordermark D, Eckert AW: (2011) Survivinexpression als prognostischer Faktor für Patienten mit Munhöhlenkarzinom. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:51-5.
  7. Kotzsch M, Magdolen V, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Eckert AW, Luther T, Baretton G, Würl P, Taubert H: (2011) Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients. BMC CANCER 11:273.
  8. Ostheimer C, Wichmann H, Kappler M, Bache M, Kotzsch M, Vordermark D: (2011) Der Plasma-Hypoxiemarker Osteopontin als Prognosefaktor für die Radiotherapie des Bronchialkarzinoms: erste Survival-Analyse. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:217-22.
  9. Rot S, Taubert H, Bache M, Greither T, Wurl P, Eckert AW, Schubert J, Vordermark D, Kappler M: (2011) A novel splice variant of the stem cell marker LGR5/GPR49 is correlated with the risk of tumor-related death in soft-tissue sarcoma patients. BMC CANCER11:429.
  10. Rot S, Taubert H, Keßler J, Bache M, Eckert A, Vordermark D, Kappler M: (2011) Inhibierung des Stammzellmarkers GPR49 in Glioblastom- und Weichteilsarkomzelllinien. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:45-9.
  11. Staab A, Fleischer M, Loeffler J, Said HM, Katzer A, Plathow C, Einsele H, Flentje M, Vordermark D: (2011) Small interfering RNA targeting HIF-1alpha reduces hypoxia-dependent transcription and radiosensitizes hypoxic HT 1080 human fibrosarcoma cells in vitro. STRAHLENTHER ONKOL, 187:252-9.
  12. Steinmann D, Bremer M, Vordermark D (2011): Verzicht auf Ganzhirnbestrahlung nach Radiochirurgie ist vertretbar. IM FOCUS ONKOLOGIE, 5:22-3.
  13. Vordermark D: (2011) Ten years of progress in radiation oncology. BMC CANCER 11(1):503.
  14. Vordermark D: (2011) Beeinflußt die Einnahme von Statinen die Tumorkontrolle nach Strahlentherapie eines Prostatakarzinoms? STRAHLENTHER ONKOL, 187:218-9.
  15. Vordermark D: (2011) Dosis-Volumen-Histogramme für die Strahlentherapie: wichtige Informationen für die Therapieplanung. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:183-4.
  16. Zschornak MP, Passin S, Keßler J, Wichmann H, Kappler M, Paschke R, Taubert H, Vordermark D, Bache M: (2011) Effekte von Betulinsäure und Bestrahlung in malignen Gliom-Zelllinien unter normoxischen und hypoxischen Bedingungen. EXP STRAHLENTHER KLIN STRAHLENBIOL, 20:59-63.
  1. Bache M, Kappler M, Rot S, Wichmann H, Hahnel A, Greither T, Said HM, Kotzsch M, Würl P, Taubert H, Vordermark D: (2010) Elevated tumor and serum levels of the hypoxia-associated protein osteopontin are associated with prognosis for soft tissue sarcoma patients. BMC CANCER, 10:132.
  2. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M: (2010) Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. RADIAT ONCOL, 5:82.
  3. Hahnel A, Greither T, Würl P, Vordermark D, Taubert H, Bache M: (2010) Prognostische Relevanz der Osteopontin-Spleißvarianten bei Weichteilsarkompatienten mit postoperativer Radiochemo- oder Chemotherapie. EXP STRAHLENTHER KLIN STRAHLENBIOL, 19:15-19.
  4. Janssen S, Meyer A, Vordermark D, Steinmann D: (2010) Radiotherapy and internet – what can patients expect? Homepage analysis of German radiotherapy institutions. STRAHLENTHER ONKOL, 186 (12):700-4.
  5. Kessler J, Hahnel A, Wichmann H, Rot S, Kappler M, Bache M, Vordermark D: (2010) HIF-1alpha inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC CANCER, 10(1):605.
  6. Kessler J, Bache M, Vordermark D: (2010) Einfluß einer HIF-1α-Inhibierung durch siRNA oder Chetomin auf die Strahlenresistenz maligner Gliom-Zelllinien. EXP STRAHLENTHER KLIN STRAHLENBIOL ,19:5-9.
  7. Kuhnt T, Sandner A, Wendt T, Engenhart-Cabillic R, Lammering G, Flentje M, Grabenbauer G, Schreiber A, Pirnasch A, Dunst J: (2010) Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. ANN ONCOL, 21(11):2284-9.
  8. Kuhnt T, Janich M.: (2010) Prinzipien der Strahlentherapie bei malignen orbitalen und periorbitalen Raumforderungen. HNO, 58(1):15-23.
  9. Machann W, Beer M, Breunig M, Stoerk S, Angermann C, Seufert I, Schwab F, Koelbl O, Flentje M, Vordermark D: (2010) Cardiac MRI findings in 20-year survivors of mediastinal radiotherapy for Hodgkin´s disease. INT J RADIAT ONCOL BIOL PHYS, Epub 20 April 2010
  10. Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D: (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in Paediatric Hodgkin`s Lymphoma: Results of the GPOH-HD-2002 study. J CLIN ONCOL, 28(23):3680-6.
  11. Ostheimer C, Wichmann H, Hahnel A, Reese T, Kappler M, Bache M, Kotzsch M, Vordermark D: (2010) Evaluation von Osteopontin und alternativen Plasmamarkern der hypoxischen Strahlenresistenz bei Patienten mit Bronchialkarzinom. EXP STRAHLENTHER KLIN STRAHLENBIOL, 19:31-36.
  12. Said HM, Supuran CT, Hagemann C, Staab A, Polat B, Katzer A, Scozzafava A, Anacker J, Flentje M, Vordermark D. (2010) Modulation of carbonic anhydrase 9 (CA9) in human brain cancer. Curr Pharm Des, 16 (29):3288-99.
  13. Taubert H, Würl P, Greither T, Kappler M, Bache M, Lautenschläger C, Füssel S, Meye A, Eckert AW, Holzhausen HJ, Magdolen V, Kotzsch M: (2010) Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients. BR J CANCER, 102(4):731-7. 
  14. Taubert H, Heidenreich C, Holzhausen HJ, Schulz A, Bache M, Kappler M, Eckert AW, Würl P, Melcher I, Hauptmann K, Hauptmann S, Schaser KD: (2010) Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC CANCER, 10:65.
  15. Vordermark D, Pelz T, Sieker F: (2010) Die Rolle der externen Strahlentherapie bei der Behandlung des Schilddrüsenkarzinoms. ONKOLOGE, 16(7):695-700.
  16. Vordermark D: (2010) Hypoxia-specific targets in cancer therapy: role of splice variants. BMC MED, 8:45.
  17. Vordermark D: (2010) Patient information and decision aids in oncology: need for communication between patients and physicians. J CLIN ONCOL, 28(29):e567.
  18. Vordermark D: (2010) Early palliative care for patients with metastastic non-small-cell lung cancer. N ENGL J MED, 363 (23):2264.
  19. Vordermark D: (2010) Stereotaktische Radiotherapie oder Wedge-Resektion bei NSCLC im Stadium I? Ein retrospektiver Vergleich. STRAHLENTHER ONKOL, 186(11), 644-6.
  20. Weiss C, Arnold D, Dellas K, Liersch T, Hipp M, Fietkau R, Sauer R, Hinke A, Rödel C: (2010) Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phase I-II trials. INT J RADIAT ONCOL BIOL PHYS, 78(2):472-8.
  1. Adler J, Paelecke-Habermann Y, Jahn P, Landenberger M, Leplow B, Vordermark D.: (2009) Patient information in radiation oncology: a cross-sectional pilot study using the EORTC QLQ-INFO26 module. RADIAT ONCOL, 4:40.
  2. Bekes K, Francke U, Schaller HG, Kuhnt T, Gerlach R, Vordermark D, Gernhardt CR.: (2009) The influence of different irradiation doses and desensitizer application on demineralization of human dentin. ORAL ONCOL, 45(9): e80-4.
  3. Bratengeier K, Meyer J, Schwab F, Vordermark D, Flentje M.:(2009) Steep dose gradients for simultaneous integrated boost IMRT. Z MED PHYS, 19:129-35. 
  4. Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, Hagen R, Pfreundner L, Schröder U, Eckel H, Hess M, Schröder M, Schneider P, Jens B, Zenner HP, Werner JA, Engenhardt-Cabilic R, Vanselow B, Blinkert P, Niewald M, Kuhnt T, Budach W, Flentje M. (2009) Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial). EUR ARCH OTORHINOLARYNGOL 266(8):1291-300.
  5. Eckert AW, Lautner MH, Schütze A, Bolte K, Bache M, Kappler M, Schubert J, Taubert H, Bilkenroth U.: (2009) Co-expression of HIF1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J ORAL PATHOL MED, Epub 25 Sep 2009.
  6. Fränzel W, Gerlach R. (2009) The irradiation of human dental tissue by X-rays and electrons – a nanoindenter study. Z MED PHYS, 19:5-10.
  7. Hagemann C, Gloger J, Anacker J, Said HM, Gerngras S, Kühnel S, Meyer C, Rapp UR, Kämmerer U, Vordermark D, Flentje M, Roosen K, Vince GH.: (2009) RAF expression in human astrocytic tumors. INT J MOL MED, 23(1):17-31.
  8. Hahnel A, Wichmann H, Kappler M, Vordermark D, Taubert H, Bache M.: (2009) Einfluss des Osteopontin auf die Strahlenresistenz der humanen Mammakarzinomzelllinie MDA-MB-231. EXP STRAHLENTHER KLIN STRAHLENBIOL 18:39-43.
  9. Hey J., Setz J., Gerlach R., Janich M., Sehlleier S., Schaller H. G., Gernhardt C. R., Kuhnt T.: (2009) Parotid-gland-sparing 3D conformal radiotherapy in patients with bilateral radiotherapy of the head and neck region – Results in clinical practice. ORAL ONCOL, 45(2):e11-7.
  10. Hey J, Setz J, Gerlach R, Vordermark D, Gernhardt CR, Kuhnt T.:(2009) Effect of cisplatin on parotid gland function in concomitant radiochemotherapy. INT J RADIAT ONCOL BIOL PHYS, 75(5):1475-80.
  11. Keßler J, Rot S, Kappler M, Vordermark D, Taubert H, Bache M.: (2009) Bestrahlung und Survivin-spezifische siRNA in mesenchymalen Stammzellen (MSC) und Weichteilsarkomen (WTS). EXP STRAHLENTHER KLIN STRAHLENBIOL 18: 93-97.
  12. Kuhnt T, Klockenbrink U, Pelz T, Wienke A, Janich M, Sandner A, Lautermann J, Vordermark D, Schubert J.: (2009) Postoperative radiotherapy versus concurrent radiochemotherapy for locally advanced squamous cell carcinoma of the oral cavity and the oropharynx. NEW ARMENIAN MED J, 3: 11-21.
  13. Kuhnt T, Friese M, Vordermark D.: Cardiac toxicity after radiotherapy for breast cancer: current concepts of associated risk and strategies of dose reduction. In: Ford TD (ed.) New Cancer Research Developments, Nova Science Publishers, New York, 2009.
  14. Said HM, Stein S, Hagemann C, Polat B, Staab A, Anacker J, Schoemig B, Theobald M, Flentje M, Vordermark D.: (2009) Oxygen-dependent regulation of NDRG1 in human glioblastoma cells in vitro and in vivo. ONCOL REP, 21(1):237-46.
  15. Said HM, Polat B, Hagemann C, Anacker J, Flentje M, Vordermark D.:(2009) Absence of GAPDH regulation in tumour cells of different origin under hypoxic conditions in vitro. BMC RES NOTES 2:8.
  16. Sehlen S, Vordermark D, Schafer C, Herschbach P, Bayerl A, Pigorsch S, Rittweger J, Domin C, Bolling T, Wypior HJ, Zehentmayr F, Schulze W, Geinitz H.: (2009) Job stress and job satisfaction of physicians, radiographers, nurses and physicists working in radiotherapy: a multicenter analysis by the DEGRO Quality of Life Work Group. RADIAT ONCOL, 4:6.
  17. Steinmann D, Schäfer C, van Oorschot B, Wypior HJ, Bruns F, Bölling T, Sehlen S, Hagg J, Bayerl A, Geinitz H, Hipp M, Vordermark D: Effects of radiotherapy for brain metastases on quality of life (QoL): prospective pilot study of DEGRO QoL Working Party. STRAHLENTHER ONKOL, 185(3):190-7.
  18. Stromiedel M, Bache M, Vordermark D, Rot S, Wichmann H, Taubert H, Kappler M.: (2009) Untersuchung der Effekte des EGFR-Targeting mittels siRNA- bzw. spezifischer Antikörper in der Weichteilsarkomzelllinie SKLMS-1. EXP STRAHLENTHER KLIN STRAHLENBIOL 18:87-91.
  19. Vordermark D, Noe M, Markert K, Wulf J, Müller G, Bratengeier K, Beckmann G, Baier F, Guckenberger M, Schiefelbein F, Schön G, Flentje M, Baier K.:(2009) Prospective evaluation of quality of life after permanent prostate brachytherapy with I-125: importance of baseline symptoms and of prostate-V150. RADIOTHER ONCOL , 91 (2):217-24.
  20. Vordermark D.: (2009) Cause-specific colostomy rates after chemoradiotherapy for anal carcinoma: cancer-related vs. treatment-related colostomy. J CLIN ONCOL, 27(18):3064.
  21. Wichmann H, Bache M, Vordermark D, Taubert H, Kappler M.: (2009) Targeting des potentiellen Hypoxiemarkers Osteopontin in humanen Sarkom-Zelllinien. EXP STRAHLENTHER KLIN STRAHLENBIOL, 18:15-9.
  1. Bache M., Kappler M., Said H. M., Staab A., Vordermark D.: (2008) Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies. CURR MED CHEM, 15(4):322-338.
  2. Dellas K., Bache M., Pigorsch S. U., Taubert H., Kappler M., Holzapfel D., Zorn E., Holzhausen H. J., Haensgen G.: (2008) Prognostic impact of HIF-1a expression in patients with definitive radiotherapy for cervical cancer. STRAHLENTHER ONKOL, 184(3):169-174.
  3. Dunst J, Debus J, Rudat V, Wulf J, Budach W, Hoelscher T, Reese T, Mose S, Roedel C, Zuehlke H, Hinke A.: (2008) Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer. Mature results of a phase II trial. STRAHLENTHER ONKOL, 184(9)450-6.
  4. Guckenberger M., Baier K., Richter A., Vordermark D., Flentje M..:(2008) Does intensity-modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only? RADIAT ONCOL, 3:3.
  5. Hagemann C, Anacker J, Gerngras S, Kühnel S, Said HM, Pater R, Kämmerer U, Vordermark D, Roosen K, Vince GH.: (2008) Expression analysis of the autosomal recessive primary microcephaly genes MCPD1 (microcephalin) and MCPH5 (ASPM, abnormal spindle-like, microcephaly associated) in human malignant gliomas. ONCOL REP, 20(2):301-8. 
  6. Hänsgen G, Grund D, Schneider A, Marnitz S, Köhler C.: (2008) Die Therapie von Frauen mit Endometriumkarzinom. ONKOLOGE 14(6):633-44.
  7. Kappler M., Taubert H., Holzhausen H.-J., Reddemann R., Rot S., Becker A., Kuhnt T., Dellas K., Dunst J., Vordermark D., Hänsgen G., Bache M.: (2008) Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer: prognostic role and correlation with tumor markers and tumor oxygenation parameters. STRAHLENTHER ONKOL, 184(8):393-9.
  8. Rödel C., Arnold D., Hipp M., Liersch T., Dellas K., Iesalnieks I., Hermann R.M., Lordick F., Hinke A., Hohenberger W., Sauer R.: (2008) Phase I-II Trial of Cetuximab, Capecitabine, Oxaliplatin, and Radiotherapy as Preoperative Treatment in Rectal Cancer. INT J RADIAT ONCOL, 70(4):994-1001.
  9. Said HM, Polat B, Staab A, Hagemann C, Stein S, Flentje M, Theobald M, Katzer A, Vordermark D.: (2008) Rapid detection of the hypoxia-regulated CA-IX and NDRG1 gene expression in different glioblastoma cells in vitro. ONCOL REP, 20(2):413-9.
  10. Semrau R., Hansemann K., Adam M., Andratschke N., Brunner T., Heinzelmann F., Hildebrandt G., Vordermark D., Zips D.: (2008) Quality of Training in Radiation Oncology in Germany – Results of a 2006 Survey by “YoungDEGRO”. STRAHLENTHER ONKOL, 184(5):239-244. 
  11. Strauss H.G., Haensgen G., Dunst J., Hayward C.R., Burger H.U., Scherhag A., Koelbl H.: (2008) Effects of anemia correction with epoetin beta in patients receiving radiochemotherapy for advanced cervical cancer. INT J GYNECOL CANCER, 18(3):515-24. 
  12. Taubert H, Bartel F, Greither T, Bache M, Kappler M, Köhler T, Böhnke A, Lautenschläger C, Schmidt H, Holzhausen HJ, Hauptmann S, Würl P. : (2008) Association of HDM2 transcript levels with age of onset and prognosis in soft tissue sarcomas. MOL CANCER RES, 6(10):1575-81.
  13. Vordermark D.: (2008) Potential and limitations of intensity-modulated radiotherapy in anal cancer. J CLIN ONCOL, 26(4):688.
  14. Vordermark D.: (2008) Temporal changes in quality of life (QoL) of primary brain tumor patients: raw QoL data from randomized trial as reference for future studies. J CLIN ONCOL, 26(12):2061-2062.
  15. Vordermark D.: (2008) Skin-sparing intensity-modulated radiotherapy of the breast. J CLIN ONCOL, 26(19):3292.
  16. Vordermark D.: (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N ENGL J MED 359(2):201.
  17. Vordermark D, Guckenberger M, Baier K, Markert K. (2008) Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity-modulated brachytherapy or EBRT for prostate cancer patients: in regard to Prada et al. (Int J Radiat Oncol Biol Phys 2007;69:95-102). INT J RADIAT ONCOL BIOL PHYS 71(1):316-317. 
  1. Capalbo G., Rödel C., Stauber R.H., Knauer S.K., Bache M., Kappler M., Rödel F.: (2007) The role of survivin for radiation therapy. Prognostic and predictive factor and therapeutic target. STRAHLENTHER ONKOL, 183(11): 593-599.
  2. Kappler M., Rot S., Taubert H., Greither T., Bartel F., Dellas K., Hänsgen G., Trott K.R., Bache M.: (2007) The effects of knockdown of wild-type survivin, survivin-2B or survivin-delta3 on the radiosensitization in a soft tissue sarcoma cells in vitro under different oxygen conditions. CANCER GENE THER, 14(12):994-1001.
  3. Kuhnt T., Friese M., Janich M., Gerlach R., Pelz T., Haensgen G.: (2007) Possibility of radiotherapy-associated cardiovascular side effects in breast cancer patients by modern radiotherapy techniques. Breast J, 13(1): 103-105.
  4. Kuhnt T., Pelz T., Qu X., Hänsgen G., Dunst J., Gellerich F.N.: (2007) Mitochondrial OXPHOS Functions in R1H Rhabdomyosarcoma and Skeletal Muscles of the Rat. NEUROCHEM RES, 32(6):973-980.
  5. Müller A.C., Diestelhorst A., Kuhnt T., Kühn R., Fornara P., Scholz H.J., Dunst J., Zietman A.L.: (2007) Organ-sparing treatment of advanced bladder cancer: paclitaxel as a radiosensitizer. STRAHLENTHER ONKOL, 183(4): 177-183.
  6. Rödel C., Liersch T., Hermann R.M., Arnold D., Reese T., Hipp M., Fürst A., Schwella N., Bieker M., Hellmich G., Ewald H., Haier J., Lordick F., Flentje M., Sülberg H., Hohenberger W., Sauer R.: (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J CLIN ONCOL, 25(1): 110-117.
  7. Said H.M., Hagemann C., Staab A., Stojic J., Kühnel S., Vince G.H., Flentje M., Roosen K., Vordermark D.: (2007) Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo. RADIOTHER ONCOL, 83(3): 398-405.
  8. Said H.M., Hagemann C., Stojic J., Schoemig B., Vince G.H., Flentje M., Roosen K., Vordermark D.: (2007) GAPDH is not regulated in human glioblastoma under hypoxic conditions. BMC MOL BIOL, 8: 55.
  9. Said H.M., Staab A., Hagemann C., Vince G.H., Katzer A., Flentje M., Vordermark D.: (2007) Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. J NEURO-ONCOL, 81(1): 27-38.
  10. Staab A., Loeffler J., Said H.M., Diehlmann D., Katzer A., Beyer M., Fleischer M., Schwab F., Baier K., Einsele H., Flentje M., Vordermark D.: (2007) Effects of HIF-1 inhibition by chetomin on hypoxia-related transcription and radiosensitivity in HT 1080 human fibrosarcoma cells. BMC CANCER, 7: 213. 
  11. Staab A., Löffler J., Said H.M., Katzer A., Beyer M., Polat B., Einsele H., Flentje M., Vordermark D.: (2007) Modulation of glucose metabolism inhibits hypoxic accumulation of hypoxia-inducible factor-1alpha (HIF-1alpha). STRAHLENTHER ONKOL, 183(7): 366-373. 
  12. Taubert H., Würl P., Greither T., Kappler M., Bache M., Bartel F., Kehlen A., Lautenschläger C., Harris L.C., Kaushal D., Füssel S., Meye A., Böhnke A., Schmidt H., Holzhausen H.J., Hauptmann S.: (2007) Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. ONCOGENE, 26(50):7170-7174. 
  13. Vordermark D.: (2007) Prophylactic radiotherapy for glioblastoma in the elderly. NEW ENGL J MED, 357(2): 195-196. 
  14. Vordermark D.: (2007) Avoiding bias in the prospective evaluation of patients with brain metastases. J CLIN ONCOL, 25(25): 4023. 
  15. Vordermark D., Lackenbauer A., Wulf J., Guckenberger M., Flentje M.: (2007) Local control in 118 consecutive high-risk breast cancer patients treated with breast-conserving therapy. ONCOL REP, 18(5): 1335-1339. 
  16. Vordermark D., Marold D., Wirth S., Keilholz L., Pfändner K., Schimpke T., Thiel H.J., Willner J., Ziegler K., Guckenberger M., Flentje M.: (2007) Patterns of care in the radiotherapy of prostate cancer in Northern Bavaria 1998-2000. STRAHLENTHER ONKOL, 183(6): 314-320. 
  17. Wuttig D., Kunze D., Fuessel S., Toma M., Stade J., Kotzsch M., Kappler M., Taubert H., Schwenzer B., Baretton G., Hakenberg O.W., Meye A., Wirth M.P.: (2007) Are overexpressed alternative survivin transcripts in human bladder cancer suitable targets for siRNA-mediated in vitro inhibition? INT J ONCOL, 30(6): 1317-24
  1. Bache M., Holzapfel D., Kappler M., Holzhausen H.J., Taubert H., Dunst J., Hänsgen G.: (2006) Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. GYNECOL ONCOL, 104(1):139-144.
  2. Bache M., Reddemann R., Said H.M., Holzhausen H.J., Taubert H., Becker A., Kuhnt T., Hänsgen G., Dunst J., Vordermark D.: (2006) Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. INT J RADIAT ONCOL, 66(5):1481-1487.
  3. Fränzel W., Gerlach R., Hein H.J., Schaller H.G.: (2006) Effect of tumor therapeutic irradiation on the mechanical properties of teeth tissue. Z MED PHYS, 16(2): 148-154.
  4. Guckenberger M., Pohl F., Baier K., Meyer J., Koelbl O., Flentje M., Vordermark D.: (2006) Influence of rectum delineation (rectal volume vs. rectal wall) on IMRT treatment planning of the prostate. STRAHLENTHER ONKOL, 182(12): 721-726.
  5. Kuhnt T., Becker A., Bloching M., Schubert J., Klautke G., Fietkau R., Dunst J.: (2006) Phase II Trial of a Simultaneous Radiochemotherapy with Cisplatinum and Paclitaxel in Combination with Hyperfractionated-Accelerated Radiotherapy in Locally Advanced Head and Neck Tumors. MED ONCOL, 23(3): 325-334.
  6. Kuhnt T., Janich M., Götz U., Gerlach R., Chiricuta I.C., Hänsgen G.: (2006) Presentation of a 3D Conformal Radiotherapy Technique for Head-and-Neck Tumors Resulting in Substantial Protection of the Parotid Glands. STRAHLENTHER ONKOL, 182(6): 325-330.
  7. Taubert H., Greither T., Kaushal D., Würl P., Bache M., Bartel F., Kehlen A., Lautenschläger C., Harris L., Kraemer K., Meye A., Kappler M., Schmidt H., Holzhausen H.J., Hauptmann S.: (2006) Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma. ONCOGENE, 26(7):1098-1100.
  8. Vordermark D., Ruprecht K., Rieckmann P., Roggendorf W., Vince G.H., Warmuth-Metz M., Kölbl O., Flentje M.: (2006) Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC CANCER, 6: 247.
  9. Vordermark D., Said H.M., Katzer A., Kuhnt T., Hansgen G., Dunst J., Flentje M., Bache M.: (2006) Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC CANCER, 6(1): 207.
  10. Vordermark D., Seufert I., Schwab F., Kölbl O., Kung M., Angermann C., Flentje M.: (2006) 3-D reconstruction of anterior mantle-field techniques in Hodgkin's disease survivors: doses to cardiac structures. Radiat Oncol, 1: 10.
  11. Vordermark D., Wulf J., Markert K., Baier K., Kölbl O., Beckmann G., Bratengeier K., Noe M., Schön G., Flentje M.: (2006) 3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: a cross-sectional quality-of-life survey. ACTA ONCOL, 45(6): 708-716.